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Introduction		Worldwide,	there	are	unacceptable	inequities	in	access	to	cancer	prevention,	treatment	and	care	for	adults	and	children	with	wide	disparities	in	mortality	and	survival.	While	the	low-income	and	middle-income	countries	(LMIC)	account	for	around	80%	of	the	global	cancer	burden,	the	financing	for	cancer	in	these	countries	only	amount	to	5%	of	the	resources	allocated	to	cancer	care	globally.1			Many	misconceptions	have	perpetuated	these	disparities,	and	created	a	‘cancer	divide’	in	access	to	treatment	and	thus	in	survival,2	with	false	perceptions	that	cancer	care	is:	(i)	unnecessary	because	the	burden	of	cancer	is	not	large	in	LMIC	(ii)	unaffordable,	for	most	LMIC	(iii)	unattainable	because	LMIC	do	not	have	adequate	human	or	physical	resources	to	support	treatment	and	care,	and	(iv)	inappropriate	in	LMIC	because	it	takes	resources	away	from	high-burden	diseases	that	have	proven	treatments	and	interventions.2			The	stark	inequities	in	financing	and	access	to	care	have	translated	to	wide	disparities	in	the	survival	of	children	with	cancer.	The	five-year	net	survival	for	acute	lymphoblastic	leukemia,	the	most	common	childhood	cancer,	range	from	less	than	50%	in	Ecuador	to	more	than	90%	in	many	high-income	countries.	However,	beyond	a	handful	of	countries	the	magnitude	of	these	inequities	in	relation	to	the	overall	survival	gap	has	not	been	reliably	quantified	in	LMICs.3		
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Yet,	these	misconceptions	are	unfounded.	For	most	children,	a	diagnosis	of	cancer	was	once	a	death	sentence.	However,	the	last	six	decades	have	produced	scientific	advances	in	the	diagnosis,	treatment	and	supportive	care	of	children	diagnosed	with	cancer	(ages	0-14	years).	In	high-income	countries,	for	many	cancers,	these	advances	have	produced	remarkable	improvements	in	five-year	net	survival,	for	example	from	less	than	5%	to	80%	for	childhood	leukaemia.4	However,	these	advances	have	not	similarly	benefited	children	with	cancer	in	LMICs	to	anything	like	the	same	extent.5			Multiple	factors	account	for	the	global	inequities	in	cancer	outcomes,	including:	disparities	in	access	to	effective	diagnostics6,	medicines,7	surgery8,	radiotherapy9,	and	advanced	stages	of	disease	when	cancer	is	diagnosed10.	Even	when	there	is	access	to	medicines	and	treatment,	financial	unaffordability	compels	many	children	to	abandon	treatment	prematurely11,	or	lack	of	supportive	care	leads	to	treatment	interruptions	or	even	death12.	In	addition,	poor	quality	care	delivered	in	weak	health	systems	in	LMICs	adversely	affects	outcomes	for	cancer	and	other	conditions	that	are	amenable	to	treatment.13	In	many	LMICs	children	with	cancer	face	multiple	barriers	in	every	step	of	care	to	survive	(panel	1).			
Panel	1:	The	child	with	cancer	in	resource-limited	settings	In	LMIC	(we	define	LMIC	according	 to	World	Bank	 income	group	classification	 in	2016	–	appendix	page	28)	unacceptable	excess	in	treatment	failure	for	children	with	cancer	results	from	a	malfunction	of	every	step	in	the	care	cascade	from	diagnosis,	to	referral	to	treatment,	follow	up	and	palliative	 care.14	 Inadequate	healthcare	 infrastructure	and	service	delivery	networks,	 limited	access	 to	quality	medicines,	 lack	of	multidisciplinary	health	workforce,	
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low-quality	of	care	adverse	socio-economic	environment,	cultural	and	educational	barriers,	and	 lack	of	awareness	both	at	 the	societal	 level	as	well	as	within	the	medical	community	result	 in	 missed	 diagnosis,	 under-ascertainment,	 delayed	 and	 under	 diagnosis	 and	suboptimal	 care	 of	 childhood	 cancer	 in	 LMIC.15,16,17	 Other	 factors	 also	 contribute	 to	suboptimal	care	and	poor	outcomes,	including:		(i)	Refusal	 and	abandonment	of	 therapy:	 refusal	 and	abandonment	of	 therapy	 is	 a	major	cause	of	therapeutic	failure	in	countries	with	limited	resources,	where	children	and	families	incur	unaffordable	direct	and	indirect	costs	of	care18,19,	and	affect	up	to	50-60%	of	children	in	some	world	regions	–	often	exceeding	all	other	causes	of	treatment	failure.11	Most	children	abandon	 early,	 usually	 after	 induction	 remission	 in	 leukaemias	 or	 at	 the	 time	 of	 radical	surgeries	(e.g.	enucleation	of	the	eye	or	amputation)	in	solid	malignancies.20,21			(ii)	Malnutrition:	the	prevalence	of	malnutrition	in	children	with	cancer	in	LMIC,	which	is	associated	with	higher	toxicity	rates,	reaches	50%	to	70%	in	some	regions	of	the	world	and	is	a	major	cause	of	decreased	survival.	22,23				(iii)	Lack	of	supportive	care:	the	ability	to	provide	state	of	the	art	curative	treatments	for	children	with	cancer	in	LMIC	is	severely	limited	by	the	lack	of	supportive	care	programmes,	most	 notably	 nutrition,	 and	 infection	 control.	 Death	 from	 infection	 during	 neutropaenic	episodes	is	much	higher	in	countries	with	limited	resources.24,25,26					(iv)	Lack	of	blood	products	and	transfusion	support:	availability	of	safe	blood	products	 is	
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another	major	limitation	to	successful	cancer	care	in	LMICs	–	a	problem	worsened	by	the	high	seroprevalence	of	HIV	and	Hepatitis	B,	which	can	be	as	high	as	10%	to	25%	among	blood	 donors	 in	 Africa.27	 Only	 13%	 of	 LMICs	 have	 a	 national	 hemovigilance	 system	 to	monitor	 and	 improve	 the	 safety	 of	 transfusions,	 and	 only	 53%	 of	 blood	 donations	 are	appropriately	screened.28			(v)	Reliance	on	traditional	and	complementary	medicine:	while	a	lack	of	awareness	of	the	population	in	about	cancer	is	a	serious	obstacle	to	access	to	treatment,	it	is	also	part	of	the	reason	why	parents	bring	their	children	to	traditional	healers	even	when	they	have	access	to	cancer	care.	This	leads	to	delayed	diagnosis	but	also	a	higher	incidence	of	use	of	traditional	and	complementary	medicine,	for	which	often	there	is	no	evidence	of	effectiveness,	among	children	undergoing	cancer	treatment	in	LMICs,	with	adverse	consequences	related	to	drug	interactions,	adherence	to	therapy,	and	treatment-related	toxicities.29			(vi)	 Lack	 of	 palliative	 and	 survivorship	 care:	 most	 LMIC	 lack	 properly	 developed	 and	implemented	palliative	care	programmes.30	Lack	of	adequate	pain	control	is	at	the	core	of	deficient	palliation	in	LMIC,	where	pain	management	may	be	available	in	less	than	50%	of	paediatric	 oncology	 units,	 and	 high-potency	 opiates	 and	 adjuvant	 medications	 for	neuropathic	pain	are	available	in	less	than	15%	of	the	countries.31			The	world	is	clearly	failing	to	meet	the	needs	of	children	with	cancer	in	LMIC.	Yet,	there	is	hope.	There	are	many	cost-effective	interventions	that	could	be	used	to	expand	access	to	cancer	prevention,	treatment	and	care.32	However,	as	with	many	other	technologies	for	
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global	health	(including	diagnostics,	medicines,	medical	devices	and	therapies)	are	challenges	related	to	(i)	availability	–	the	technology	is	either	not	available	to	people	in	LMICs,	(ii)	accessibility	–	technology	exists	but	is	not	accessible	(due	to	unaffordability,	distribution	challenges	or	lack	of	human	resources)	or,	(iii)	acceptability	–	technology	is	available	and	accessible	but	not	used	due	to	inertia	or	lack	of	acceptability	to	users.33			New	evidence	and	several	recent	developments	worldwide	have	created	an	impetus	to	eliminate	these	disparities	in	treatment	and	outcome	for	children	with	cancer.	The	Third	Edition	of	Disease	Control	Priorities	(DCP3),	a	worldwide	collaboration	involving	leading	academic	institutions,	countries	and	development	agencies,	has	identified	cost-effective	interventions	for	childhood	cancer	in	LMICs	to	show	that	treating	cancers	such	as	Burkitt	lymphoma,	and	Hodgkin	lymphoma	is	very	cost	effective	and	can	be	delivered	even	in	medical	centres	with	the	least	capability,	while	treating	Wilms	tumour	and	acute	lymphoblastic	leukaemia	is	either	cost-effective	or	very	cost-effective	and	along	with	intraocular	retinoblastoma	could	be	delivered	in	medical	centres	with	greater	capability.	DCP3	also	suggested	that	effective	treatment	for	sarcomas,	brain	tumors,	acute	myeloid	leukemia,	high-risk	neuroblastoma,	and	other	retinoblastomas	could	be	delivered	in	medical	centres	with	the	highest	level	of	capability.34	DCP3	has	also	identified	healthcare	delivery	platforms,	such	as	primary	health	care	centres,	district	hospitals,	teaching	hospitals	and	specialist	hospitals	for	children,	which	could	be	used	to	deliver	cost-effective	interventions.35			
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Further,	the	Lancet	Commission	on	Global	Health	2035	has	highlighted	the	“enormous	payoff	from	investing	in	health”	in	terms	of	health	and	economic	benefits	for	individuals,	household	and	countries,	arguing	that	it	is	possible	to	achieve	“dramatic	health	gains”	and	to	achieve	convergence	in	health	outcomes	between	low-income	countries	and	upper-middle-income	countries	within	a	generation.	The	Commission	concluded:	“progressive	universalism	would	yield	high	health	gains	per	dollar	spent	and	poor	people	would	gain	the	most	in	terms	of	health	and	financial	protection”.36	While	the	Lancet	Commission	on	Global	Health	2035	did	not	focus	on	childhood	cancer,	it	made	a	strong	case	for	‘investing	in	health’	to	realise	health	and	economic	benefits.	A	similar	case	could	be	made	for	expanding	coverage	of	cost-effective	interventions	to	tackle	childhood	cancer	and	to	eliminate	unacceptable	worldwide	inequities	in	access	to	care	and	health	outcomes.	The	timing	is	right	for	a	global	push	to	expand	the	coverage	of	care	for	childhood	cancers.	There	is	a	strong	global	momentum	to	achieve	the	universal	health	coverage	(UHC)	–	a	target	(Target	3.7)	of	the	third	Sustainable	Development	Goal.37			In	2017,	the	World	Health	Assembly	Resolution	on	Cancer	Prevention	and	Control	called	on	Member	States	to	implement	health	promotion	and	risk	factor	reduction	for	cancer,	and	to	address	inequity	in	access	to	early	detection	and	appropriate	treatment,	including	pain	relief	and	palliative	care.38	With	this	mandate,	in	2018,	the	World	Health	Organisation	(WHO)	launched	the	Global	Initiative	for	Childhood	Cancer	to	support	governments	in	building	and	sustaining	high-quality	childhood	cancer	programmes	to	reach	at	least	a	60%	five-year	overall	survival	for	children	with	the	six	commonest	childhood	cancers	globally	by	2030.39	Achieving	this	goal	will	require	prioritisation	of	childhood	cancers	at	global	and	
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national	levels,	increased	funding	and	stronger	health	systems.40	This	is	especially	in	the	case	of	sub-Saharan	Africa	where	health	systems	are	weak,	and	the	population	of	children	is	projected	to	grow	from	320	million	in	2015	to	more	than	720	million	in	2050.41		However,	evidence	is	needed	to	demonstrate	the	opportunities	for	reducing	disparities	in	access	and	outcomes,	and	to	make	a	case	for	investing	in	worldwide	scale-up	of	cost-effective	interventions	for	childhood	cancer,	and	for	their	inclusion	in	UHC.			The	aim	of	the	Lancet	Oncology	Commission	on	Sustainable	Cancer	Care	for	Children	(the	Commission)	is	to	present	new	evidence	to	justify	investments	in	scale-up	of	interventions	for	childhood	cancers	in	LMICs	to	reduce	disparities	and	improve	outcomes.	The	Commission	provides	a	comprehensive	analysis	of	the	challenges	and	opportunities	in	relation	to	childhood	cancers	and	costs	and	benefits	of	scaling	up	cost-effective	interventions	and	their	inclusion	in	UHC.	It	identifies	examples	of	good	practice	in	different	settings	and	potential	solutions	with	packages	of	care	that	could	be	scaled	up	globally.	It	quantifies	the	investment	needed	to	scale	evidence-based	interventions	and	the	health	and	economic	benefits	of	such	investments	globally	to	develop	a	compelling	case	for	investing	in	management	of	childhood	cancers.			The	Commission	report	is	organised	in	seven	sections.	Section	one	provides	an	analysis	of	the	global	challenge	of	childhood	cancer	by	providing	a	review	of	published	literature	and	estimates	for	incidence	and	survival	of	childhood	cancers.	This	section	also	presents	new	analyses	on	the	current	and	projected	incidence	of	childhood	cancers	and	survival	in	
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different	countries	globally.	Section	two	provides	an	analysis	of	the	current	service	coverage	levels	for	childhood	cancers,	funding	allocated	to	childhood	cancers	in	national	cancer	plans	and	global	research	funding.		Section	three	examines	the	current	evidence	on	the	cost	of	providing	cancer	services	in	different	settings	and	case	studies	of	successful	examples	of	LMICs	that	have	developed	cancer	services.	Section	four	presents	a	new	analysis	of	costs,	health	and	economic	benefits	of	expanding	cancer	services	and	the	economic	returns	to	investing	in	childhood	cancer	care.	Section	five	provides	new	analyses	on	the	package	of	services	that	are	necessary	for	providing	care	to	children	with	cancer	in	varied	settings,	and	capabilities	needed	to	deliver	them.	Section	six	discusses	actions	for	expansion	of	services	for	children	with	cancer,	potential	funding	that	could	be	mobilised	to	support	expansion	of	care	to	children	with	cancer	globally,	and	the	roles	different	stakeholders	could	play	in	this	expansion	process.	Finally,	we	propose	ambitious	but	achievable	targets	and	a	call	to	action	for	sustainable	care	for	children	with	cancer	around	the	world.		
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SECTION	1:	THE	CHALLENGE		Accurate	estimates	of	childhood	cancer	incidence	are	critical	for	understanding	the	current	and	 future	 burden	 of	 disease	 and	 the	 demand	 for	 health	 services,	 and	 to	 inform	 policy-	makers	 in	 priority	 setting	 and	 planning	 decisions	 to	 ensure	 development	 of	 appropriate	responses	at	global	and	country	level.			The	Commission	undertook	a	series	of	reviews	of	published	literature	and	examined	existing	data	to	identify	studies	on	global	and	national	estimates	of	incidence,	survival	and	mortality,	as	well	as	composite	measures	of	the	burden	of	childhood	cancer	(such	as	disability-adjusted	life-years	[DALYs]42).				A	scoping	review	of	studies	of	childhood	cancer	burden	undertaken	by	the	Commission	and	published	in	2000-2018	(details	of	which	are	published	elsewhere)43	identified	four	major	studies:	(i)	International	Incidence	of	Childhood	Cancer	(IICC-3)44,45	(ii)	GLOBOCAN	2012,	published	in	201546	(iii)	CONCORD	(CONCORD-3),3	and	(iv)	Global	Burden	of	Disease	Study	(GBD)	2016	on	cancer	covering	the	period	1990-201647.	These	studies	differ	in	data	sources,	the	criteria	for	assessing	data	quality	and	inclusion	of	data	in	the	analyses,	the	analytical	and	modelling	approaches	used	to	estimate	the	burden	of	cancer,	and	the	subsets	of	childhood	malignancies	 and	 countries.	Their	 estimates	of	 incidence	 and	mortality	 also	differ	 (panel	2).43			
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Panel	2:	Comparison	of	published	studies	measuring	incidence,	survival	and	
mortality,	and	the	burden	of	disease	for	childhood	cancer	The	International	Agency	for	Research	on	Cancer	(IARC),	in	collaboration	with	the	International	Association	of	Cancer	Registries,	used	population-level	data	collected	by	cancer	registries	to	estimate	the	incidence	of	childhood	cancer.	The	findings	of	the	study	were	published	in	the	Lancet	Oncology	in	2017,44	coinciding	with	the	publication	of	the	International	Incidence	of	Childhood	Cancer,	volume	3	(IICC-3)45.			IICC-3,	published	in	2017,	included	data	from	153	registries	in	62	countries	to	examine	the	incidence	rates	in	children	and	adolescents	aged	0-19	years,	diagnosed	during	2001-2010	with	leukaemias,	lymphomas,	central	nervous	system	tumours,	neuroblastoma,	retinoblastoma,	soft	tissue	sarcoma,	germ	cell	tumours,	epithelial	tumours,	cancers	of	kidney,	liver	or	bone,	or	a	residual	category	of	‘other	and	unspecified’	malignancies.	Only	11%	of	included	registries	were	from	LMICs.44		GLOBOCAN	2012,	published	in	2015,	used	data	from	375	registries	to	model	incidence	and	mortality	rates	for	leukaemias,	Hodgkin	lymphoma,	non-Hodgkin	lymphoma,	cancers	of	central	nervous	system,	kidney	and	liver,	and	Kaposi	sarcoma	in	children	aged	0-14	years	for	184	countries	in	2012.	Just	7%	of	the	registries	were	from	LMICs.46		CONCORD-3,	published	in	2018,	used	individual	patient	data	from	322	registries	in	71	countries	to	examine	5-year	net	survival	(cumulative	probability	of	surviving	up	to	5-years	since	diagnosis	after	correcting	for	other	causes	of	death)	from	acute	lymphoblastic	
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leukaemia,	lymphomas,	and	central	nervous	system	tumours	among	children	(aged	0-14)	for	2000-2014.	Only	5%	of	the	registries	were	from	LMICs.3		GBD	2016,	published	in	2017,	used	data	from	562	registries	in	93	countries	to	model	incidence,	prevalence,	mortality	and	disability	adjusted	life-years	for	acute	lymphoblastic	leukaemia,	acute	myeloid	leukaemia,	Hodgkin	lymphoma,	non-Hodgkin	lymphoma,	and	cancers	of	the	central	nervous	system,	kidney	and	liver,	in	children	and	adolescents	aged	0-19	years	for	195	countries	over	the	period	1990-2016.	Only	12%	of	the	registries	were	from	LMICs.47		
	
Published	studies	on	estimates	of	incidence	of	childhood	cancers	Worldwide	regional	estimates	of	childhood	cancer	incidence	for	the	year	2018	undertaken	by	IARC	for	this	Commission	by	modelling	based	on	cancer registry	data	suggests	age-	standardised	rates	ranging	from	59.5	per	million	person-years	for	children	aged	0-14	years	(95%	uncertainty	interval	[UI]	54.9-64.1)	in	sub-Saharan	Africa	to	175.1	(95%	UI	163.6-186.5)	in	Southern	Europe	(table	1).	The	largest	number	of	estimated	new	cases	was	in	South	Central	Asia	(44,098)	and	the	lowest	in	Oceania	(1,362).	Age	standardised	incidence	rates	(ASR)	for	leukaemias	were	the	highest	(49.1	per	million	person-years	for	children	aged	0-14	years;	95%	UI	47.9-50.4),	followed	by	central	nervous	system	tumours	(ASR	30.4;	95%	UI	29.4-31.4)	(table	1).			
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Table	1:	Estimated	age-standardised	incidence	rates	of	childhood	cancer	per	million	
population	by	world	region,	for	2018	
World	Region	 Age-standardised	
rate	
95%	
uncertainty	
interval	
Number	of	
cases	
Africa,	North	 105.4	 83.2-127.6	 7,587	Africa,	Sub-Saharan	 59.5	 54.9-64.1	 24,584	America,	Caribbean	 148.7	 133.1-164.3	 8,780	America,	South	 135.7	 128.8-142.6	 13,500	America,	North	 167.8	 162.9-172.6	 10,781	Asia,	Eastern	 163.2	 156.9-169.4	 43,144	Asia,	South	Central	 79.9	 70.7-89.1	 44,098	Asia,	South	Eastern	 122.9	 108.5-137.4	 20,280	Asia,	Western	 146.5	 134.4-158.6	 11,162	Europe,	Eastern	 159.1	 150.0-168.2	 7,305	Europe,	Northern	 150.6	 142.0-159.2	 2,658	Europe,	Southern	 175.1	 163.6-186.5	 3,791	Europe,	Western	 169.2	 162.0-176.4	 4,852	Oceania	 152.0	 137.2-166.8	 1,362		 	 	 	Data	source:	International	Agency	for	Research	in	Cancer	For	countries	in	each	sub-region	please	refer	to	appendix	page	2		There	were	an	estimated	91,463	leukaemia	cases	in	2018,	with	an	ASR	of	49.1	per	million	population,	followed	by	57,457	central	nervous	system	tumours	(ASR	30.4;	95%	UI	29.4-31.4)	(table	2).		
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Table	2:	Estimated	age	standardised	incidence	rates	per	million	population	for	
childhood	cancers	by	cancer	type	
	
Area	 Age-standardised	
rate	 95%	uncertainty	
interval	
Number	of	
cases	
Leukaemia	 49.1	 47.9-50.4	 91,463	Lymphomas	 15.5	 14.7-16.3	 30,410	Central	nervous	system	tumours	 30.4	 29.4-31.4	 57,457	Sympathetic	nervous	system	 10.9	 10.3-11.5	 19,235	Retinoblastoma	 4.7	 4.2-5.1	 8,132	Renal	tumours	 8.3	 7.8-8.8	 14,871	Hepatic	tumours	 2.6	 2.2-2.9	 4,578	Bone	tumours	 5.7	 5.3-6.1	 11,597	Soft	tissue	sarcomas	 9.1	 8.7-9.5	 17,327	Germ	cell	&	gonadal	tumours	 5.3	 5.0-5.7	 10,230	Epithelial	tumours	&	melanoma	 5.1	 4.7-5.5	 10,332	Other	&	unspecified	 1.1	 0.9-1.2	 1,977	Data	source:	International	Agency	for	Research	in	Cancer	
	However,	as	with	earlier	estimates,	these	figures	are	derived	by	modelling	the	number	of	observed	and	registry-reported	cases,	and	projecting	the	rates	to	countries	without	cancer	registries.	They	do	not	account	for	underreporting.43				
	The	incidence	estimates	from	GLOBOCAN	2012	and	GBD	2016	were	more	comprehensive	in	their	coverage,	in	terms	of	the	cancer	types	and	the	number	of	countries	for	which	estimates	were	made.	However,	for	the	many	countries	with	missing	data	incidence	and	mortality	rates	were	extrapolated	from	other	sources.		The	incidence	estimates	for	these	
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two	studies	differed	by	between	5%	and	47%	depending	on	the	cancer.	For	the	number	of	deaths	the	differences	varied	between	5%	and	52%.	The	difference	in	the	modelled	estimates	of	the	total	number	of	cancers	diagnosed	worldwide	each	year	in	children	and	adolescents	(aged	0-19	years)	was	large,	estimated	by	GLOBOCAN	as	163,284	cases	and	by	GBD	2016	as	240,942	cases.	43		
	
Published	Studies	on	Survival	from	Childhood	Cancers	In	2018,	the	CONCORD	programme,	led	by	the	Cancer	Survival	Group	at	the	London	School	of	Hygiene	and	Tropical	Medicine	in	England,	published	its	third	report	(CONCORD-3),3	covering	global	trends	in	population-based	cancer	survival	based	on	individual	records	for	over	37	million	patients	diagnosed	with	one	of	18	common	cancers	during	2000-2014.3			These	18	cancers	represent	75%	of	the	global	cancer	burden.	Data	were	provided	by	322	population-based	cancer	registries	in	71	countries	and	territories	that	are	home	to	67%	of	the	world's	population.	CONCORD-3	reported	age-standardised	five-year	net	survival,	which	is	corrected	for	competing	causes	of	death	(background	mortality)	and	the	higher	competing	risks	of	death	in	the	elderly.48	Information	on	background	mortality	was	derived	from	complete	life	tables	of	all-cause	mortality	in	the	general	population,	specific	for	country	or	region,	single	year	of	age,	sex,	single	calendar	year	and,	where	relevant,	race/ethnicity.3			CONCORD-3	included	the	three	most	common	childhood	cancers:	acute	lymphoblastic	leukaemia,	lymphomas	and	brain	tumours.	The	second	cycle	of	the	CONCORD	programme	
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(CONCORD-2)49,	including	children	(0-14	years)	diagnosed	in	1995-2009,	had	reported	five-year	net	survival	for	childhood	leukaemias.50	Combined	results	from	CONCORD-2	and	CONCORD-3	indicated	that	during	the	20-year	period	from	1995-1999	to	2010-2014,	age-standardised	5-year	net	survival	for	acute	lymphoblastic	leukemia	had	increased	by	10%	or	more	in	14	countries,	including	three	upper-middle-income	countries	(China,	Turkey	and	Lithuania).3			The	CONCORD	Central	Analytic	Team	performed	more	detailed	analyses	of	survival	by	morphologic	sub-type	for	this	Commission.	Age-standardised	5-year	net	survival	for	childhood	cancers	varied	widely	by	country-income	status	(table	3).	Only	reliable,	age-standardised	estimates	are	shown	in	Table	3	with	a	range	of	lowest	and	highest	values	in	LMIC	where	data	are	available	to	show	the	range	and	not	report	just	a	single	‘outlier’	that	was	either	very	high	or	very	low.											
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Table	3:	Lowest	and	highest	age-standardised	5-year	net	survival	(%)	for	children	
diagnosed	with	cancer	during	2010-2014,	by	country	and	country-income	group	
	
 Source:	Survival	estimates	provided	by	the	Concord	programme	*	Data	with	100%	coverage	of	the	national	population		Note:	Morphology	groups	included	in	Table	3	are	based	on	the	second	tier	of	the	International	Classification	of	Childhood	Cancer	3rd	edition	(ICCC-3).	Therefore,	age-standardised	survival	estimates	are	for	all	astrocytomas	combined	and	for	all	embryonal	tumours	combined.	ICCC-3	does	include	a	third,	more	granular	tier	for	embryonal	tumours,	but	not	for	astrocytomas.	We	chose,	however,	not	to	estimate	survival	separately	for	embryonal	tumour	subtypes	in	this	third	tier	(medullolastoma,	primitive	neuro-ectodermal	tumour,	medulloepithelioma,	and	atypical	teratoid/rhabdoid	tumour),	because	small	numbers	would	not	have	allowed	production	of	robust,	age-standardised	survival	estimates.			Age-standardised	 five-year	 net	 survival	 for	 children	 diagnosed	with	 acute	 lymphoblastic	
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leukaemia	 in	 LMICs	 during	 2010-2014	 varied	 between	 47.8%	 in	 Ecuador	 and	 85.7%	 in	Belarus.	The	highest	value	was	seen	in	Finland	(95.1%).	For	acute	myeloid	leukaemia,	five-year	survival	among	LMICs	during	2010-2014	ranged	from	29.5%	in	Ecuador	to	80.2%	in	Costa	Rica.	The	highest	value	was	seen	in	Denmark	(84.1%).			The	global	range	of	age-standardised	five-year	net	survival	for	brain	tumours	was	broad.	For	astrocytomas,	age-standardised	five-year	net	survival	for	2010-2014	in	LMICs	ranged	from	65.6%	 in	Russia	 to	82.2%	 in	Belarus,	and	between	43.5%	 in	Korea	and	88.4%	 in	 Ireland	among	high-income	countries.	Age-standardised	5-year	net	survival	for	children	diagnosed	with	embryonal	tumours	during	2010-2014	varied	between	43.5%	in	Belarus	and	56.0%	in	Turkey	among	LMICs,	and	from	48.6%	in	Finland	to	77.0%	in	Sweden.	
	IICC-3,	GLOBOCAN	2012	and	GBD	2016	and	the	CONCORD-3	have	all	noted	inherent	limitations	in	their	estimates	of	incidence,	survival	and	mortality.	These	limitations,	which	are	summarised	in	panel	3,	need	to	be	addressed.	3,44,45,46,47			
	
	
	
Panel	3:	Limitations	of	published	studies	on	estimates	of	global	incidence,	survival	
and	mortality	of	childhood	cancers	The	first	limitation	is	the	paucity	of	population-based	cancer	registries	in	LMICs.	For	example,	in	their	estimates	IICC-344	and	CONCORD	studies3,49	included	data	from	reporting	cancer	registries	in	50%	of	high-income	countries,	41%	upper-middle-income	countries,	
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21%	of	low-middle-income	countries	and	only	10%	of	low-income	countries.	The	“Global	Initiative	in	Cancer	Registration”,	launched	by	IARC	and	other	global	partners	in	2011,	is	attempting	to	remedy	this	situation	through	provision	of	training	and	capacity	building.51			The	second	limitation	is	that	the	quality	of	the	data	that	area	available	from	population	based	cancer	registries	is	variable.	The	iterative	process	of	queries	back	and	forth	to	submitting	registries,	used	both	by	the	IICC-3	and	CONCORD	studies	to	produce	their	reports,	clearly	improved	the	quality	of	the	data.	For	IICC-3,	IARC	reported	that	of	the	153	included	registries,	47%	(72)	did	not	initially	meet	quality	standards.	CONCORD	studies	collected	data	to	a	common	protocol	and	ran	standardised	quality	control	procedures	on	all	data	sets.	3,44,49		The	third	limitation	with	the	data	at	hand	is	that	they	only	include	children	who	have	first	been	diagnosed,	and	then	registered	in	the	population	based	cancer	registry.	Some	children	who	are	treated	in	the	private	sector	or	in	other	countries	might	not	be	included	in	the	cancer	registry.	As	alluded	to	previously,	the	low	incidence	rates	in	sub-Saharan	Africa	and	other	world	regions	may	well	reflect	under-ascertainment,	not	inherently	lower	rates	of	cancer.	Both	GLOBOCAN	201246,52,53	and	the	Global	Burden	of	Disease	studies47,54	have	attempted	to	adjust	for	the	presumed	levels	of	under-diagnosis,	or	under-registration	of	cancers	that	are	diagnosed,	by	modeling	expected	incidence,	using	the	anticipated	ratio	of	cancer	mortality	to	cancer	incidence.	However,	this	is	less	than	ideal,	because	it	is	inherently	dependent	on	timely	and	accurate	death	registration,	which	may	be	at	least	as	incomplete	as	cancer	registration	in	many	of	these	countries.55	
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	The	fourth	limitation	is	the	data	needed	for	estimating	survival,	which	is	likewise	dependent	on	accurate	public	data	systems	to	ascertain	vital	status.	Most	cancer	registries	use	a	system	of	‘passive	follow-up’	to	determine	the	date	on	which	a	cancer	patient	is	last	known	to	be	alive,	by	linking	tumour	registration	records	to	official	data	systems,	such	as	a	regional	or	national	index	of	all	deaths,	or	social	insurance,	health	insurance,	electoral	registers,	or	hospital	records.	In	the	absence	of	efficient	public	record	systems,	or	difficulty	in	accessing	them,	a	high	proportion	of	registered	patients	may	be	lost-to-follow	up.	In	Morocco,	for	instance,	33%	of	patients	included	in	CONCORD-3	report	were	lost	to	follow-up	and	35%	were	censored,	in	contrast	for	US	registries,	1.5%	of	patients	were	lost	to	follow-up	and	none	were	censored.3			A	further	limitation	in	examining	the	current	status	of	childhood	cancer	survival	was	that	while	CONCORD	-3	included	brain	tumours,	it	did	not	include	the	other	solid	tumours	that	represent	about	one-third	of	childhood	malignancies.			Many	of	the	childhood	solid	tumors,	such	as	Wilms	tumor,	germ	cell	tumors	and	retinoblastoma,	are	highly	curable	with	surgery	and	chemotherapy.	In	an	attempt	to	assess	the	current	status	of	survival	of	children	with	solid	tumors,	the	Commission	undertook	a	systematic	review	of	the	literature	published	between	January	2011	and	December	2016	to	assemble	current	literature	on	survival	for	solid	tumors	of	childhood	that	were	not	included	in	the	CONCORD-3	(appendix	pp.	3-8).			
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The	search	identified	4,695	articles;	only	59	fulfilled	the	inclusion	criteria	during	the	5-year	period	(see	appendix	page	8	for	PRISMA	diagram).	Among	these	publications,	11	upper-middle-income	countries,	nine	lower-middle-income	countries,	and	four	low-income	countries	were	represented.	China	contributed	the	most	studies	(13);	reports	from	low-income	countries	Malawi	(4	studies),	Botswana	(1	study),	Senegal	(1	study),	and	Uganda	(1	study)	were	included.	The	distribution	of	articles	by	disease	was	as	follows:	retinoblastoma	(17),	germ	cell	tumors	(2),	hepatoblastoma	(3),	rhabdomyosarcoma	(7),	osteosarcoma	(5),	Ewing	sarcoma	(2),	Kaposi	sarcoma	(3),	neuroblastoma	(6),	soft	tissue	sarcoma	(2)	and	Wilms	tumor	(12)	(appendix	pp.	8-15).		In	the	studies	included,	inconsistent	methodology	on	censoring,	minimal	follow-up	times,	and	only	reporting	results	by	risk	group	made	overall	survival	estimates	difficult	to	summarise	but	estimates	varied	greatly	from	10%	at	5-years	in	soft	tissue	sarcoma	(Cambodia)	to	98%	at	5	years	in	retinoblastoma	(China).	
	
Modelling	to	estimate	global	incidence,	survival	and	mortality	of	childhood	cancers	The	available	studies	on	incidence	and	survival	of	childhood	cancers	have	limitations.	Both	IICC-3	and	CONCORD-3	were	based	on	the	analysis	of	individual	records	of	children	diagnosed	with	cancer,	but	they	could	include	relatively	few	registries	from	LMICs.	The	three	groups	of	childhood	cancer	included	in	CONCORD-3		(leukaemias,	lymphomas	and	brain	tumours)	account	for	about	66%	of	all	childhood	tumours.		While	GLOBOCAN	2012	and	the	GBD	2016	provided	incidence	estimates	for	a	larger	number	of	countries	than	IICC-3,	but	they	used	models	and	projections	to	estimate	incidence	where	registry	data	were	not	
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available,	and	did	not	take	into	account	health	system	weaknesses	that	might	have	led	to	under-diagnosis	or	under-reporting	of	cancer	cases	where	registries	do	exist.		Given	these	limitations	the	Commission	developed	its	own	modelling	approach	to	develop	country-level	and	global	estimates	of	cancer	incidence,	survival	and	mortality	from	childhood	cancer	in	LMICs.		
	
Estimating	the	Global	Incidence	of	Childhood	Cancers	Development	of	meaningful	policies	to	effectively	address	the	burden	of	childhood	cancer	in	LMICs	requires	reliable	estimates	of	the	current	incidence	of	childhood	cancer,	deaths	from	cancer	and	net	survival	in	countries,	just	as	a	global	response	requires	global	estimates.			We	developed	a	proprietary	model,	the	Global	Childhood	Cancer	(GCC)	microsimulation	model;	an	individual	level	simulation	model	described	in	detail	elsewhere56	and	briefly	in	appendix	(pp.	16-17).			The	model	synthesizes	demographic,	epidemiologic,	and	health	system	data	from	well-established	data	sources	to	estimate	childhood	cancer	incidence	for	the	following	World	Bank	income	groups:	low-income	countries,	lower-middle-income	countries,	upper-middle-income	countries,	and	high-income	countries57	This	analytic	framework	leverages	informative,	albeit	incomplete	data	from	cancer	registries	in	combination	with	country-level	data	on	health	systems	related	to	access	to	primary	health	care	and	appropriate	referral,	to	provide	estimates	of	the	total	incidence	of	childhood	cancer	globally	for	children	
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aged	0-14	years.			Using	the	Global	Childhood	Cancer	model	and	the	incidence	rates	that	have	been	computed	and	published	elsewhere	using	this	model,56	we	estimate	that	there	will	be	413,000	(95%	UI	389,000	to	444,000)	incident	cases	of	childhood	cancer	worldwide	in	2020,	of	which	232,000	(95%	UI	223,000	to	246,000)	cases	will	be	diagnosed	and	181,000	cases	undiagnosed	(95%	UI,	163,000	to	200,000)	(table	4).			
Table	4:	Projected	number	of	children	diagnosed	with	cancer	in	2020		
	
Income	
Group	
Total	
(95%	UI)	
Number	
diagnosed	
(95%	UI)	
Number	
undiagnosed	
(95%	UI)	
Proportion	of	
total	who	are	
undiagnosed	
(95%	UI)	Global	 413,000	(389,000-444,000)	 232,000	(223,000-246,000)	 181,000	(163,000-200,000)	 44%	(42%-46%)	LIC	 85,000	(75,000-98,000)	 38,000	(34,000-42,000)	 47,000	(41,000-56,000)	 55%	(54%-57%)	LMIC	 208,000	(191,000-228,000)	 102,000	(96,000-109,000)	 106,000	(94,000-119,000)	 51%	(49%-54%)	UMIC	 90,000	(83,000-98,000)	 64,000	(62,000-66,000)	 26,000	(19,000-34,000)	 29%	(23%-35%)	HIC	 31,000	(30,000-32,000)	 29,000	(28,000-30,000)	 2,000	(1,000-3,000)	 6%	(4%-9%)		The	estimated	magnitude	of	under-reporting	varies	substantially	by	income	group:	over	50%	in	low-income	countries	(55%,	95%	UI,	54	to	57%)	and	lower-middle-income	countries	(51%,	UI	49	to	54%),	less	than	30%	in	upper-middle-income	countries	(29%,	95%	UI	23	to	35%),	and	approximately	5%	for	high-income	countries	(6%,	95%	UI,	4	to	9%)	(figure	1).			These	findings	suggest	that	health	system	barriers	to	access	and	referral,	especially	in	low-
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income	countries	and	lower-middle-income	countries,	lead	to	substantial	under-diagnosis	of	childhood	cancer	with	44%	of	cases	undiagnosed.				For	every	child	with	cancer	who	is	diagnosed	and	reported	in	a	cancer	registry	in	these	settings,	another	child	with	cancer	may	be	missed.	
	
Figure	1:	Projected	numbers	of	incident	childhood	cancer	cases	–	total,	diagnosed	and	
undiagnosed	for	2020,	by	World	Bank	income	group	(based	on	2016	classification)		
		Taking	into	account	current	projections	of	population	growth,	we	estimate	that	globally	there	will	be	13.7	(95%	UI	12.5	to	15.0)	million	new	cases	of	childhood	cancer	from	2020	to	2050,	of	which	around	3.4	million	(95%	UI	2.9-4.0)	will	be	in	low-income	countries	and	an	estimated	6.9	million	(95%	UI	6.0-7.8)	in	low-middle-income	countries.	In	2020	to	2050,	the	projected	number	of	new	cases	of	childhood	cancer	in	upper-middle	income	countries	
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will	be	2,509,000	(95%	UI		2,239,000-2,801,000)	and	939,000	(95%	UI	884,000-999,000)	in	high-income	countries	(table	5).		At	current	levels	of	health	system	performance	(access	and	referral),	the	model	estimates	that	6.1	(95%	UI,	5.4	to	6.9)	million	cases	of	childhood	cancers,	accounting	for	44.9	%	of	total	cases	(95%	UI	42.9%-46.7%)	of	childhood	cancers,	will	be	undiagnosed	in	2020-2050.	In	low-income	and	lower-middle	income	countries,	the	number	of	children	with	cancer	who	are	undiagnosed	will	exceed	those	who	are	diagnosed.	With	the	current	projected	demographic	trends,	the	annual	number	of	childhood	cancer	incident	cases	is	projected	to	diverge	by	country	income	groups,	with	high	and	upper-middle-income	countries	experiencing	a	decline	in	cases,	while	low-income	and	lower-middle-income	countries	experience	continued	increases	due	to	population	growth	(figure	2).		
	
	
	
	
	
	
	
	
	
	
	
	
	
Table	5:		Projected	number	of	new	childhood	cancer	cases	in	2020	to	2050	for	
children	aged	0-14	years	
Income		
Group	
Projected	number	of	childhood	cancer	incident	cases	(95%	UI)	
Total		
(95%UI)	
Diagnosed	
(95%UI)	
Undiagnosed		
(95%	UI)	Global	 13,659,000	(12,542,000-15,002,000)	 7,532,000	(7,025,000-8,118,000)	 6,128,000	(5,445,000-6,937,000)	LIC	 3,359,000	 1,518,000	 1,842,000	
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(2,923,000-3,951,000)	 (1,335,000-1,744,000)	 (1,571,000-2,228,000)	LMIC	 6,852,000	(6,004,000-7,779,000)	 3,358,000	(2,971,000-3,773,000)	 3,494,000	(2,988,000-4,039,000)	UMIC	 2,509,000	(2,239,000-2,801,000)	 1,773,000	(1,611,000-1,934,000)	 736,000	(557,000-975,000)	HIC	 939,000	(884,000-999,000)	 883,000	(836,000-930,000)	 56,000	(38,000-83,000)	
	
Figure	2:	Projected	new	childhood	cancer	incident	cases	between	2020	and	2050	–	by	
World	Bank	income	group	(based	on	2016	classification)	
	Our	modelling	suggests	that	childhood	cancer	is	substantially	under-diagnosed,	especially	in	south	Asia	and	sub-Saharan	Africa	(including	western,	eastern,	and	southern	Africa).	An	estimated	one	in	two	new	cases	of	childhood	cancer	in	sub-Saharan	Africa	are	missed	due	to	health	system	constraints	in	access,	diagnosis	and	referral.	The	findings	indicate	that	in	addition	to	improving	treatment	for	childhood	cancer,	health	systems,	particularly	in	low-income	countries,	low-middle-income	countries	and	upper-middle-income	countries	must	be	strengthened	to	accurately	diagnose	and	effectively	care	for	all	children	with	cancer	–	an	important	action	we	discuss	in	more	detail	later	in	the	Commission	report.	
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	Although	our	model-based	estimates	should	be	interpreted	in	light	of	data	limitations	in	cancer	registries	and	the	various	assumptions	underlying	or	model,	the	model	had	a	high	level	of	accuracy	compared	with	available	observed	data.	For	example,	our	model	predictions	of	diagnosed	incidence	rates	are	consistent	with	country-specific	registry	data	and	they	reflect	geographical	variation	in	cancer	incidence	and	heterogeneity	in	health	systems	between	and	within	countries,	and	our	global	estimates	of	the	number	of	diagnosed	cases	are	similar	to	estimates	by	IARC44	and	GBD	201647.	Furthermore,	our	model	accurately	predicted	the	total	number	of	childhood	cancer	cases	reported	from	several	high-income	countries	with	national	data.	
	
Modelling	to	estimate	the	number	of	deaths	from	childhood	cancers	We	extended	the	Global	Childhood	Cancer	microsimulation	model,	described	in	detail	elsewhere56	and	briefly	in	appendix	panels	1	and	2	(pp.	16-19),	to	project	the	number	of	childhood	cancer	deaths	worldwide	between	2020	and	2050	for	children	diagnosed	and	undiagnosed	with	cancer.			Using	the	Global	Childhood	Cancer	microsimulation	model,	we	projected	the	annual	number	of	childhood	cancer	deaths	between	2020	and	2050	in	children	diagnosed	and	undiagnosed	with	cancer	(figure	3).	
	
Figure	3:	Projected	childhood	cancer	deaths	between	2020	and	2050	(diagnosed	and	
undiagnosed)		
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 We	estimated	that	in	2020	there	would	be	328,000	deaths	(95%	UI	304-357,000)	from	childhood	cancers	globally	(diagnosed	and	undiagnosed),	projected	to	rise	to	390,000	a	year	by	2050	(95%	CI	342,000-446,000).	The	largest	number	of	deaths	is	projected	to	occur	in	lower-middle-income	countries	(208,000	in	2050	(95%	UI	168,000-252,000),	but	the	largest	increase	is	projected	to	be	in	low-income	countries	from	82,000	(95%	UI	(72,000-96,000)	to	128,000		(95%	UI	(107,000-154,000)	(table	6).		We	estimate	that	between	2020	and	2050,	cumulatively,	11,108,000	children	(95%	UI,	10,067,000-12,351,000)	will	die	from	childhood	cancer	if	no	additional	investments	are	made	to	improve	access	to	healthcare	services	or	childhood	cancer	treatment	(table	6).	These	estimates	reflect	deaths	from	all	cancer	cases	(diagnosed	and	undiagnosed).			
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	The	total	number	of	deaths	from	childhood	cancer	between	2020	and	2050	is	projected	to	be	highest	in	lower-middle-income	countries,	with	6,095,000	deaths	(95%	UI	5,301,000-6,960,000)	followed	by	low-income	countries	where	the	number	is	projected	to	reach	3,249,000	(95%	UI	2,806,000-3,826,000).		A	staggering	9,344,000	(95%	UI	8,338,000	-	10,461,000)	children,	accounting	for	84.1%		(95%	UI	81.6%-86.2%)	of	the	total	deaths,	is	projected	to	occur	in	low-income	and	lower-middle-income	countries	(table	6).	
	
Table	6:	Projected	numbers	of	childhood	cancer	deaths	(cumulative,	2020	to	2050)	
in	children	aged	0-14	years	diagnosed	and	undiagnosed	with	cancer		
	
Income	
Group		
Projected	number	of	
annual	childhood	
cancer	deaths	2020		(95%UI)	
Projected	number	of	
annual	childhood	
cancer	deaths	2050		(95%UI)	
Projected	cumulative	
number	of	childhood	
cancer	deaths	2020-2050	
(95%	UI)	Global	 328,000	(304,000-357,000)	 390,000	(342,000-446,000)	 11,108,000	(10,067,000-12,351,000)	LIC	 82,000	(72,000-96,000)	 128,000	(107,000-154,000)	 3,249,000	(2,806,000-3,826,000)	LMIC	 184,000	(167,000-203,000)	 208,000	(168,000-252,000)	 6,095,000	(5,301,000-6,960,000)	UMIC	 54,000	(47,000-63,000)	 46,000	(39,000-55,000)	 1,531,000	(1,305,000-1,799,000)	HIC	 8,000	(7,000-9,000)	 7,000	(6,000-9,000)	 233,000	(209,000-264,000)	
	
	
Estimating	the	global	survival	levels	for	childhood	cancers	To	ascertain	current	survival	levels	from	childhood	cancers	globally,	especially	in	low-income	countries	and	middle-income	countries,	for	which	comprehensive	estimates	are	lacking,	the	Commission	used	the	Global	Childhood	Cancer	microsimulation	model	to	simulate	childhood	cancer	survival	for	200	countries/territories	worldwide	for	2015.	The	
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Global	Childhood	Cancer	microsimulation	model	is	described	in	detail	elsewhere56	and	briefly	in	appendix	panels	1	and	2	(pp.	16-19).			We	developed	a	survival	module	to	model	5-year	net	survival	for	all	childhood	cancers	diagnosed,	taking	into	account	clinical	and	epidemiologic	factors,	including	country-specific	treatment	variables,	such	as	the	availability	of	chemotherapy,	radiation	and	surgery.		The	detailed	methodology	for	the	survival	module	is	provided	in	the	Lancet	Oncology	publication	on	survival	for	children’s	cancers.58		To	develop	and	parameterise	the	survival	module	of	the	Global	Childhood	Cancer	microsimulation	model,	the	CONCORD	program	provided	5-year	net	survival	estimates	for	each	of	the	three	main	childhood	cancer	types	(leukaemias,	lymphomas,	and	brain	tumors),	which	were	disaggregated	into	the	subtypes	within	each	broader	category,	as	specified	by	the	International	Classification	of	Childhood	Cancer	third	edition.45	These	were	acute	lymphoblastic	leukaemia/lymphoblastic	leukaemia	and	acute	myelogenous	leukaemia,	Hodgkin	lymphoma	and	Non-Hodgkin	lymphoma,	ependymoma/choroid	plexus	tumours,	embryonal	brain	tumours,	astrocytomas,	and	other	types	of	glioma.			These	modelled	estimates,	reported	in	detail	elsewhere,58	suggest	very	wide	variation	between	countries	and	world	regions	in	5-year	net	survival	for	all	cancer	combined	(figure	4).	Survival	estimates	are	reported	for	all	of	the	continents.			
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In	2015-2019,	average	global	five-year	net	survival	was	37.4%	(95%	UI	34.7%-39.8%),	but	it	ranged	from	11.6%	(95%	UI	8.7%-14.8%)	in	Africa	to	39.6%	(95%	UI	35.1%-43.6%)	in	Asia,	55.0%	(95%	UI	51.2-58.7%)	in	Latin	America	and	the	Caribbean,	64.4%	(95%	UI	58.9-69.2)	in	Oceania,	74.3%	(95%	UI	71.9%-76.4%)	in	Europe,	and	83.0%	(95%	UI	81.6%-84.4%)	in	North	America.	In	sub-continental	regions,	the	modelled	estimates	of	5-year	net	survival	were	lowest	in	Eastern	Africa	at	8.1%	(95%	UI	4.4%-13.7%)	and	Western	Africa	at	8.5%	(95%	UI	4.9%-13.0%).58		
	
Figure	4:	Estimated	5-year	net	survival	for	childhood	cancers	diagnosed	(all	cancer	types;	2015-2019)	
	Source:	Ward	et	al.		Lancet	Oncology	2019	There	was	a	large	difference	between	the	modelled	estimates	of	5-year	net	survival	for	all	cancers	combined	of	7.4%	(95%	UI	5.0%-10.7%)	for	low-income	countries	and	79.8%	(95%	UI	78.7%-80.8%)	in	high-income	countries.	The	modelled	estimates	of	5-year	net	survival	in	Africa	were	less	than	25%	(range	2.3%	to	24.1%)	for	each	tumour	type	
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examined,	whereas	for	North	America	the	estimates	for	almost	every	tumour	type	were	greater	than	60%,	ranging	from	57.8%	for	hepatic	carcinoma	to	98.2%	for	malignant	melanoma.	For	some	tumour	types,	the	difference	between	world	regions	in	5-year	net	survival	for	tumour	types	was	huge.	For	example,	in	Africa,	estimate	for	5-year	net	survival	for	central	nervous	system	germ-cell	tumour	was	2.3%	(95%	UI	0.8%-5.3%),	compared	with	80.9%	(95%	UI	69.4-89.9%)	in	North	America.58		The	analysis	undertaken	by	the	Commission	reveals	large	variation	in	incidence	rates,	death	rates,	and	5-year	net	survival	for	childhood	cancers	between	countries,	world	regions,	and	World	Bank	country-income	groups,	with	a	clear	gradient	of	high	death	rates	and	poor	survival	in	low-income	countries	and	lower-middle-income	countries.	The	analysis	also	highlights	the	paucity	of	high	quality	cancer	registry	data	for	children’s	cancers	in	LMICs.				In	section	two	we	explore	the	current	global	and	country-level	financing	and	coverage	of	healthcare	services	for	childhood	cancers.	We	provide	new	analyses	of	global	funding	for	research	from	public	and	philanthropic	sources	for	childhood	cancers.	Using	country-level	case	studies	this	section	also	examines	in	depth	how	childhood	cancer	diagnosis,	treatment	and	care	is	funded,	provided	and	incorporated	in	priority	setting	process	in	selected	LMICs.	
	
SECTION	2:	CURRENT	FINANCING	FOR	CHILDHOOD	CANCER	SERVICES	AND	
RESEARCH	AND	COVERAGE	OF	CHILDHOOD	CANCER	CARE			
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We	examined	published	studies	on	financing	and	coverage	of	healthcare	services	for	childhood	cancers.	We	also	examined	publicly	available	databases	on	national	health	budgets,	country	studies	on	national	health	accounts	on	health	financing,	as	well	as	published	studies	on	national	health	plans	or	national	cancer	plans,	to	ascertain	the	level	of	funding	allocated	to	childhood	cancers.	Further,	we	undertook	a	detailed	analysis	of	research	funding	for	childhood	cancers	using	publicly	available	data	and	bibliometric	analysis.		We	also	undertook	detailed	analysis	in	five	LMICs	to	ascertain	how	childhood	cancer	services	were	prioritised,	financed	and	delivered.		We	present	the	findings	below.	
	
Current	Financing	of	Childhood	Cancer	Programs	The	WHO	Global	Health	Expenditure	Database	(which	utilises	data	from	publicly	available	national	health	budgets,	budget	related	documentation,	or	National	Health	Accounts	studies	and	generates	estimates	when	data	are	not	available)	is	the	“global	reference	for	health	expenditure	estimates	in	all	WHO	Member	States”.	However,	it	has	no	data	on	funding	for	childhood	cancers	either	from	domestic	or	external	sources.	59	Nor	does	the	Organization	for	Economic	Cooperation	and	Development	(OECD)	Health	Statistics,	“the	most	comprehensive	source	of	comparable	statistics	on	health	and	health	systems	across	OECD	countries”,	which	has	data	on	International	Disease	Category	of	‘Neoplasms’,	but	with	no	breakdown	of	figures	for	children.60		Similarly,	the	OECD	data	on	Development	Finance,	which	has	the	most	comprehensive	data	on	Official	Development	Assistance,	and	collates	funding	from	donor	countries,	multinational	organizations,	private	donors,	and	foundations,	provides	no	data	financing	for	childhood	cancers.61	Thus	we	know	little	on	country-level	or	global	financing	for	childhood	cancers.	
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Analysis	of	National	Health	and	Cancer	Control	Plans	Well-designed	and	implemented	national	cancer	control	plans	are	an	important	tool	for	improving	cancer	care.62		In	2017,	the	World	Health	Assembly	Resolution	70.12	(2017)	affirmed	the	commitment	of	the	WHO	member	states	to	developing	and	implementing	national	cancer	control	plans	“inclusive	of	all	age	groups”.63		However,	a	recent	published	analysis	of	527	national	cancer	plans	(or	cancer-related	plans)	from	156	countries	found	that	childhood	cancer	care	was	mentioned	in	plans	of	only	65	(42%)	countries,	but	no	data	were	provided	on	financing	childhood	cancers.	There	were	regional	differences:		53%	of	the	countries	in	the	WHO	European	and	Eastern	Mediterranean	regions	and	43%	of	the	countries	in	the	Western	Pacific	region	had	plans	that	included	childhood	cancer,	but	only	a	quarter	to	a	third	of	the	countries	in	other	world	regions	had	plans	with	any	mention	of	childhood	cancer.	64	Further	analysis	of	the	data	available	from	154	countries	included	in	the	study,64	showed	that	of	the	90	countries	with	a	national	cancer	control	plan,	61	(68%)	mentioned	childhood	cancer	in	at	least	one	national	plan;	in	contrast,	of	the	64	countries	that	did	not	have	a	national	cancer	control	plan	but	had	an	NCD	plan,	only	5	(8%)	mentioned	childhood	cancer.		The	plans	in	high-income	countries	were	twice	as	likely	to	include	childhood	cancer	as	those	in	LMICs.		Altogether,	plans	were	twice	as	likely	to	mention	cancer	in	adults	than	in	children.	However,	although	childhood	cancer	is	mentioned	in	these	plans,	few	details	are	provided	about	proposed	actions	or	the	financing	of	these	actions	across	the	care	continuum,	or	about	the	monitoring	
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and	evaluation	of	their	effects.64	This	is	similar	to	findings	in	an	earlier	analysis	of	national	cancer	control	plans	and	childhood	cancer	in	Africa.65		
	
Health	Service	Coverage	for	Childhood	Cancers			There	are	no	systematic	global	data	on	the	availability	of	childhood	cancer	services	or	country	capacities	to	manage	childhood	cancer.	In	LMICs,	government,	private	sector	and	not-for-profit	foundations	have	created	cancer	centres	with	varying	scope	and	capacity.	National	cancer	centres	are	typically	located	in	tertiary	hospitals	university	teaching	hospitals.	These	institutes	tend	to	be	in	capitals	or	major	cities,	providing	different	levels	of	comprehensive	services	and	coverage,	but	dedicated	childhood	cancer	centres	also	exist.	66	In	most	low-income	countries,	private	sector	centres,	which	provide	care	for	children	with	cancer,	have	evolved	without	adequate	regulatory	standards.67		
	
Research	Funding	for	Childhood	Cancers		The	Commission	undertook	a	detailed	analysis	of	research	funding	from	public	and	philanthropic	sources	for	childhood	cancers	for	the	period	2008-2016	using	Dimensions	database	(https://www.dimensions.ai),	which	is	an	inter-linked	research	information	system	that	uses	automated	methods	to	collate	monthly	data	on	research	funding	from	open-access	web-based	sources,	and	manually	sourced	information	directly	from	funders.	The	methodology	for	the	analysis	is	described	elsewhere	and	briefly	presented	in	appendix	panel	3	(p	20).	68		
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The	analysis	of	Dimensions	database	data	revealed	that	during	the	period	2008-2016,	total	global	funding	for	all	childhood	cancer	research	was	$2.0	billion,	with	average	funding	of	$226·8	million	per	year	over	the	nine-years;	with	an	additional	$80.3	million	dollars	estimated	per	year	from	other	major	funders	not	included	in	the	Dimensions	database.			Based	on	trends	within	the	Dimensions	data,	excluding	a	research	infrastructure	investment	of	$24	million	in	2011-13,	overall	yearly	funding	of	childhood	cancer	research	fell	from	$222·9	million	in	2011	to	$215·3	million	in	2015.	New	funding	awarded	each	year	varied	substantially	from	a	high	of	$256·0	million	in	2014	to	$160·0	million	in	2015.68		Of	the	$2.0	billion	of	total	research	funding	identified	for	the	nine-year	study	period,	around	$771·8	million	(37·9%)	was	for	‘general	paediatric	oncology’	(including	$181·6	of	investment	in	research	infrastructure	to	support	new	research	centres	and	networks).	When	funding	was	evaluated	by	tumour	type,	leukaemia	(and	other	myeloproliferative	and	myelodysplastic	diseases)	received	$448·8	million	(22·0%)	of	the	total	funding	followed	by	$329.6	million	for	central	nervous	system	tumours	(16·2%).	The	funding	for	neuroblastoma	and	peripheral	nerve	cell	tumours	was	$181·2	million	(8·9%).	A	further	$309·0	million	(15·2%)	was	awarded	for	research	into	all	other	tumour	types,	with	$86.4	million	awarded	for	malignant	bone	tumours	(4.2%),	$85.9	million	for	soft	tissue	and	extraosseous	sarcomas	(4.2%),	but	just	$16.9	million	for	retinoblastomas	(0.8%)	and	$10·3	million	for	germ	cell	tumours	(0.5%).	68		
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When	the	funding	was	compared	to	the	burden	of	childhood	cancers	(as	measured	by	age-standardised	incidence	per	million	person-years	in	children)	there	was	relative	underfunding	of	research	for	lymphomas	(including	Burkitt	lymphoma	which	accounts	for	a	large	proportion	of	childhood	cancers	in	sub-Saharan	Africa),	retinoblastomas,	renal	tumours	and	germ	cell	and	gonadal	tumours.	68		In	terms	of	funding	for	stages	of	research	(pre	clinical,	Phase	I,	II,	III,	and	phase	IV	post-	trial/healthcare	delivery	research),	$1·2	billion	(59·3%))	was	awarded	for	pre-clinical	research		($643·8	million	of	which	went	towards	investigating	the	biology	and	aetiology	of	childhood	cancers),		$525·3	million	(25·7%)	for	Phase	I,	II	or	III	clinical	trials	or	‘cross	disciplinary’	(i.e.	research	that	included	several	stages	of	the	research	pipeline,	and	$193	million	(9.5%)	for	infrastructure	but	just	$113·0	million	(5·5%)	was	spent	on	improving	healthcare	delivery	for	children	with	cancer.68			By	area	of	research	focus	$806·4	million	(39·5%)	of	the	total	research	spend	was	awarded	to	research	on	the	biology	and	aetiology	of	childhood	cancers,	$236·8	million	(11·6%)	for	survivorship	research,	$111·4	million	(5·5%)	for	diagnosis	and	prognosis	research,	with	just	$18·1	million	(0·9%)	on	research	related	to	the	prevention	of	childhood	cancers.68		Around	$1.6	billion	of	the	funding	(77·7%)	was	awarded	to	USA-based	institutions,	$105.4	million	(5.2%)	to	institutions	based	in	the	United	Kingdom,	$98.1	million	(4.8%)	in	Canada,	$37.8	million	in	Australia,	$31.5	million	(1.6%)	in	France,	$24.3	million	(1.2%)	in	Germany	
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and	$23.9	million	(1.2%)	in	Sweden.	Less	than	0.1%	of	the	funding	was	allocated	to	institutions	based	in	LMICs.68			The	annual	amount	of	research	funding	for	childhood	cancers	of	$226.8	million	per	year,	of	which	less	than	0.1%	is	awarded	to	LMICs	on	average,	is	relatively	low,	compared	to	$4.8	billion	of	research	funding	from	58	public	and	philanthropic	sources	awarded	to	cancer	research	for	all	ages	in	the	single	year	2008,69	and	$5.45	billion	in	2011	and	$5.39	billion	in	2015	allocated	to	cancer	research	for	all	ages	by	the	National	Institutes	of	Health	in	the	United	States70,	and	the	$1.3	billion	awarded	to	HIV	(in	LMICs)	and	the	$611	million	for	malaria	related	research	in	2017	alone68.	
	
Priority	setting	for	childhood	cancers:	case	studies	from	five	countries	As	part	of	the	Commission,	we	examined	the	political,	social,	and	economic	factors	which	influence	health	system	priority-setting	on	childhood	cancer	funding	and	care	in	five	LMICs,	namely	El	Salvador,	Ghana,	Guatemala,	India	and	the	Philippines.	The	methodology	is	presented	in	detail	elsewhere	and	summarised	in	appendix	panel	4	(pp.	21-22)71,72			In	each	of	the	five	countries	studied,	philanthropic	organizations,	foundations	or	private	institutions	had	been	the	first	to	establish	services	for	childhood	cancer,	often	working	with	international	partners	(panel	4).	Childhood	cancer	had	not	been	a	priority	in	the	publicly	funded	health	systems	of	these	countries	due	to	political	instability	and	competing	policy	priorities.	However,	the	respondents	in	the	study	countries	noted	that	the	global	momentum	for	UHC,	a	target	for	SDG	3,35	had	created,	particularly	in	El	Salvador	and	the	
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Philippines,	a	window	of	opportunity	to	include	childhood	cancers	in	the	political	discourse	for	priority	setting	and	incorporate	childhood	cancer	care	in	essential	benefits	package	(panel	4).		
Panel	4:	Prioritisation	of	childhood	cancers	in	universal	health	coverage	In	El	Salvador,	the	2010-2014	National	Strategic	Program	for	the	Promotion	of	Health:	Prevention	and	Control	of	Non-Communicable	Chronic	Diseases,	and	the	2015	National	Policy	on	Integrative	Care	for	People	with	Cancer	includes	cancer	prevention	and	screening	as	a	priority	does	not	mention	childhood	cancers.73,74	Funding	for	cancer	care	for	children	is	largely	from	local	philanthropic	and	private	contributions	mobilised	by	Fundacion	Ayudame	a	Vivir,	a	local	foundation,	and	channeled	to	the	national	childhood	cancer	programme,	which	received	only	one	third	of	its	budget	from	the	government.75	Childhood	cancer	care	is	provided	through	a	collaboration	established	in	1993	involving	the	publicly	funded	Hospital	Nacional	de	Niños	Benjamin	Bloom,	St	Jude	Children’s	Research	Hospital	in	the	US,	and	Fundacion	Ayudame	a	Vivir.76	In	2008,	the	creation	of	a	separate	day-clinic,	Centro	Medico	Ayudame	a	Vivir,	financed	by	the	Fundacion	Ayudame	a	Vivir,	next	to	Hospital	Bloom,	has	expanded	capacity	to	care	for	children	with	cancer.		In	Guatemala,	however,	there	is	no	discernable	national	plan	that	includes	childhood	or	adult	cancers	as	a	priority.77,78	Childhood	cancer	care	is	provided	through	a	children’s	cancer	hospital,	Unidad	Nacional	de	Oncologia	Pediatrica	(UNOP).	UNOP	is	a	public-private	partnership	established	in	2000	involving	Guatemala’s	Ministerio	de	Salud	Publica	y	Asistencia	Social,	St.	Jude	Children’s	Research	Hospital	in	the	USA,	and	Fundacion	Ayudame	
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a	Vivir	Guatemala,	a	local	foundation.79	UNOP	covers	an	estimated	47%	of	expected	cases,	mainly	from	Guatemala	City.	Although,	health	insurance	coverage,	provided	by	the	Instituto	Guatemalteco	del	Seguro	Social,	does	benefit	a	small	proportion	of	the	population,	most	families	of	children	with	cancer	incur	high	out-of-pocket	costs	for	care.	To	address	major	gaps	in	access	and	funding	of	treatment	and	associated	costs,	Ayudame	a	Vivir	Guatemala	actively	mobilises,	pools	and	channels	funds	from	philanthropic	donations,	civil	society,	academia,	private	industry	and	external	partners	to	Unidad	Nacional	de	Oncologia	Pediatrica.			In	the	Philippines,	which	has	a	highly	decentralised	health	system	with	more	than	7,000	islands	communities,	care	for	children	with	cancer	is	provided	through	more	than	30	centres	with	varied	levels	of	capacity,	but	just	three	of	these	centres	have	designated	units	and	multidisciplinary	teams	that	can	provide	comprehensive	cancer	care.80,81	The	Philippines	is	expanding	UHC,	which	now	includes	standard	risk	acute	lymphoblastic	leukemia	in	the	benefits	package,	with	commensurate	expansion	of	insurance	coverage	and	treatment	capacity	to	expand	access.82		The	‘Z	Benefits’	programme,	created	by	PhilHealth	Insurance	Corporation,	provides	comprehensive	coverage	to	children	diagnosed	with	acute	lymphoblastic	leukaemia	for	children	admitted	to	hospital	but	unable	to	meet	high	out-of-pocket	care	costs.83	In	addition,	the	Medicine	Access	Program,	which	operates	in	conjunction	with	the	Z	Benefit,	provides	free	chemotherapy	for	all	solid	tumours	and	for	patients	diagnosed	with	acute	lymphoblastic	leukaemia	who	are	not	enrolled	in	the	Z	benefits	package.84	Further,	the	‘no-balance	billing’	system	created	for	those	admitted	to	hospitals	for	care	helps	to	absorb	additional	costs	for	the	patients	entitled	to	the	Z	Benefits	
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programme.85	However,	despite	these	developments,	financial	and	physical	access	barriers	remain	due	to	the	highly	fragmented	funding	and	service	delivery	system	in	the	Philippines.	The	National	Cancer	Control	Act	and	the	Universal	Health	Care	Act	enacted	as	laws	in	February,	2019,	and	provide	for	further	increase	in	financing,	extension	of	the	benefits	package	to	include	additional	cancer	types,	and	expansion	of	service	coverage	by	developing	a	nationwide	network	of	comprehensive	cancer	centres	that	will	provide,	beyond	the	urban	hubs,	high	quality	services	for	children	with	cancer	across	the	country	in	accordance	with	clinical	guidelines	and	an	accountability	framework	for	safety	and	quality.86		In	India,	the	National	Programme	for	Prevention	and	Control	of	Cancers,	Diabetes,	Cardiovascular	Diseases,	and	Stroke,	and	the	National	Cancer	Control	Programme	of	the	Ministry	of	Health	and	Family	Welfare	does	not	prioritise	childhood	cancer.87	Hence,	alternative	governance	and	care	delivery	models	have	emerged	for	childhood	cancers,	which	include	a	mix	of	public,	private,	philanthropic	and	state	actors.	For	example,	the	Tata	Memorial	Hospital	in	Mumbai,	in	the	state	of	Maharashtra,	which	was	established	in	1941	by	the	Sir	Dorabji	Tata	Trust.	It	was	initially	managed	independently	then	transferred	in	1957	to	the	Ministry	of	Health	and	Family	Welfare.	In	1962,	the	management	of	the	hospital	and	its	Cancer	Research	Institute,	established	as	the	Tata	Memorial	Centre,	was	transferred	to	the	Department	of	Atomic	Energy,	responsible	to	the	Prime	Minister’s	Office.			The	Tata	Memorial	Centre	operates	as	a	centre	of	excellence,	with	state-of-the-art	facilities,	which	provides	high	quality	clinical	services	as	well	as	research	pertaining	to	children	with	
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cancer.	It	receives	funding	from	multiple	sources,	including	Tata	Trust,	the	federal	government	through	the	Department	of	Atomic	Energy	(a	more	stable	source	of	funding	compared	to	state	funds	for	health),	private	and	public	insurance	schemes	for	providing	care,	corporate	donations,	and	philanthropy	from	individual	donors	and	non-governmental	organizations.	Tata	Memorial	Centre’s	Improving	Pediatric	Cancer	Care	and	Treatment	(ImPaCCT)	Foundation,	funded	from	philanthropic	sources,	enables	access	to	comprehensive	cancer	care	for	children	regardless	of	socioeconomic	background	by	defraying	medical	costs,	provides	nutritional	support	for	patients	and	organises	free	accommodation	with	psychosocial	services	for	caregivers	–	an	holistic	approach	that	helps	to	reduce	abandonment	of	treatment.88		In	Ghana,	Ghana	Health	Services,	an	autonomous	Public	Service	institution,	is	responsible	for	providing	most	of	the	public	healthcare	services,	according	to	polices	and	direction	of	the	ministry.	Healthcare	services	for	childhood	cancers	are	provided	through	two	public	tertiary-care	teaching	hospitals,	which	are	independent	of	Ghana	Health	Service.	This	independence	from	the	ministry	of	health	means	that	the	teaching	hospitals	have	limited	influence	on	priority	setting.89		National	Health	Insurance	Fund,	financed	by	general	taxation,	does	not	provide	coverage	for	all	treatments	and	drug	costs	related	to	childhood	cancer.90	There	is	no	dedicated	financing	of	childhood	cancer	in	the	Non-Communicable	Disease	Control	Program	or	National	Cancer	Plan.91	Instead,	the	little	funding	available	for	childhood	cancers	comes	from	international	agencies	or	external	philanthropic	organisations,	who	typically	allocate	their	funds	to	communicable	disease	and	general	health	services	for	women	and	children,	but	for	whom	childhood	cancer	is	not	a	priority.	92	
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The	case	studies	reveal	the	considerable	variation	in	the	governance,	financing,	organizational	design	and	service	provision	for	childhood	cancers	in	the	countries	examined.	Prioritisation	of	childhood	cancers	in	national	health	policy	agendas	also	varies	across	the	countries	studied.	Arguably,	childhood	cancer	is	a	national	priority	only	in	the	Philippines,	which	has	included	acute	lymphoblastic	leukaemia	in	the	health	insurance	benefits	package,	with	plans	to	extend	the	number	of	conditions	covered	as	part	of	the	UHC	expansion,	combined	with	the	development	of	a	network	of	services	to	expand	access	to	high-quality	cancer	care	beyond	urban	settings.	This	experience	is	not	shared	by	the	other	four	countries	studied,	however,	where	childhood	cancers	are	not	part	of	health	insurance	benefits,	and	service	coverage,	access	and	financial	protection	benefit	a	few.	Instead,	in	these	countries,	foundations	and	philanthropic	institutions	have	taken	the	lead	to	establish	services	for	children	with	cancer,	often	through	innovative	partnerships	involving	government,	private	sector,	civil	society,	external	funders,	and	external	institutions	involved	in	childhood	cancer	care	in	high-income	countries.			In	LMICs	collaborations	and	‘twinning’	arrangements	have	undoubtedly	helped	in	expansion	of	cancer	care	for	some	children.93	There	are	examples	of	successful	initiatives	aimed	at	addressing	gaps	in	childhood	cancer	care,	but	these	tend	to	be	selective	(e.g.	focusing	on	a	single	cancer)	or	benefit	selected	populations	(e.g.	those	able	to	access	cancer	centres	in	urban	areas)	(panel	5).	These	collaborations,	which	tend	to	establish	dedicated	centres	located	in	urban	centres,	and	benefit	those	who	can	access	them,	have	not	reached	scale	to	convincingly	impact	on	mortality	and	survival	at	population	level,	particularly	in	
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large	and	populous	countries.94,95	As	a	result,	in	LMICs,	where	childhood	cancer	care	is	not	incorporated	into	UHC,	disparities	in	coverage	and	access	exist.	
	
Panel	5:	Examples	of	successful	initiatives	addressing	gaps	in	childhood	cancer	care		Despite	the	global	gaps	in	access	to	care,	quality	of	treatment,	and	outcomes	for	children	with	cancer,	there	are	examples	of	initiatives	aimed	at	addressing	policy,	financing,	global	advocacy,	psychosocial,	and	workforce	gaps,	which	provide	models	that	can	be	integrated	into	global	and	national	solutions.	For	example,	in	El	Salvador,	Guatemala,	and	India,	prioritisation	of	the	development	of	programs	to	address	refusal	and	abandonment	of	care,	has	resulted	in	a	substantial	improvements	on	treatment	outcomes,	highlighting	the	critical	role	of	psychosocial	packages	in	comprehensive	childhood	cancer	care.	96,97,98			A	key	principle	of	successful	paediatric	cancer	treatment	is	the	delivery	of	care	by	skilled	professional	nurses.	However,	specialized	education	and	training	is	generally	unavailable	for	nurses	in	LMICs;	this	lack	of	training,	coupled	with	high	workload	and	cultural	and	organizational	barriers	contribute	to	the	disparity	in	outcomes	and	overall	survival.99	However,	there	are	examples	of	cost-effective	and	sustainable	educational	initiatives	to	address	this	workforce	gap,	as	illustrated	by	an	internationally	supported	programme	designed	to	implement	global	nursing	standards	in	Guatemala	that	has	shown	to	promote	the	provision	of	quality	nursing	care.100		Optimization	of	care	has	shown	to	be	possible	even	in	the	poorest	countries	as	exemplified	by	the	design	of	effective	regimens	for	Burkitt	lymphoma,	one	of	the	most	common	cancers	
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in	Africa,	adapted	to	the	socioeconomic	conditions,	the	available	supportive	care,	and	the	patients’	co-morbidities.101	For	example,	in	Malawi,	a	simple	protocol	costing	less	than	$50	per	28-day	cycle	resulted	in	1-year	survival	of	48%.102	And	in	Uganda,	the	cost	per	Disability	Adjusted	Life	Year	(DALY)	averted	in	a	cohort	of	children	with	Burkitt	lymphoma	was	$97.103			The	long-term	commitment	intrinsic	to	twinning	relationships	is	critical	to	their	success,	as	it	provides	a	strong	framework	to	facilitate	the	development	of	scalable	strategies	that	incorporate	dedicated	initiatives	in	education,	capacity	building	and	research.104,105,106		
	
The	availability	of	childhood	cancer	services	in	countries	of	low-income	and	middle-
income			There	is	no	systematic	analysis	of	the	availability,	capacity	and	quality	of	services,	care	delivery	models	and	financing	of	childhood	cancers	in	all	LMICs.	However,	findings	of	selected	surveys	involving	a	few	countries	reveal	substantial	variation	in	the	availability	of	paediatric	cancer	units,	and	overall	management	of	childhood	cancers.107			In	LMICs,	incorporation	of	childhood	cancers	in	benefits	packages	varies.	For	example,	starting	with	acute	lymphoblastic	leukaemia,	Mexico	has	gradually	incorporated	childhood	cancers	in	its	health	insurance	for	poor	populations	(Seguro	Popular)108,	whereas	when	expanding	UHC	Turkey	was	able	to	provide	health	insurance	coverage	and	a	network	of	cancer	centres	for	all	cancer	types	in	children.109,110	Similarly,	Chile	and	China	have	incorporated	childhood	cancer	treatment	packages	within	the	framework	of	UHC	together	
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with	the	development	of	nationwide	networks	for	their	implementation	and	monitoring,	to	achieve	population-based	advances	and	to	demonstrate	national	models	for	effective	scale-up.111,112	However,	even	with	limitations	and	resource	constraints,	experience	from	LMICs	suggests	that	when	services	are	accessed,	demonstrable	improvements	in	survival	from	childhood	cancers	is	possible.	For	example,	5-year	event-free	survival	of	60.8%	was	achieved	in	five	countries	of	Central	America	(Costa	Rica,	El	Salvador,	Guatemala,	Honduras,	Nicaragua)	in	children	with	Hodgkin	lymphoma	despite	no	access	to	radiotherapy,113	which	is	a	critical	treatment	modality	for	some	children	with	this	cancer	in	high-income	countries.	Similarly,	3-year	event-free	survival	of	59.4%	was	achieved	in	children	with	acute	lymphoblastic	leukaemia	in	five	countries	of	Central	America	(Costa	Rica,	El	Salvador,	Honduras,	Nicaragua	and	Panama).114At	select	treatment	centres	in	India	and	China	5-year	event-free	survival	for	acute	lymphoblastic	leukaemia	was	even	higher,	at	72.1	%	and	72.7%	respectively.115,116			Selected	sub-Saharan	African	centres	in	Kenya,	Nigeria,	Tanzania	have	achieved	52%	2-year	event-free	survival	in	children	with	Burkitt	lymphoma,	and	Burkina-Faso,	Cameroon,	Ivory	Coast,	Madagascar,	Mali	and	Senegal	51%	2-year	overall	survival,	despite	lack	of	capabilities	for	‘supportive	care’,	which	constrains	the	intensity	of	treatment	provided.117,118	In	Malawi,	one	of	the	poorest	countries	in	sub-Saharan	Africa,	selected	centres	have	achieved	5-year	overall	survival	of	46%	for	Wilms	tumour.119			Many	LMICs	have	benefited	from	twinning	arrangements,	which	have	helped	to	strengthen	capacity	for	clinical	services,	improve	research	and	education,	expand	access	to	healthcare	
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services	and	improve	service	quality	–	and	contributed	to	improved	outcomes.120	
,121,122,123,124,125,126,127	However,	local	capacity	can	and	should	be	built	to	achieve	scale	and	population	level	impact.	Given	the	potential	to	achieve	demonstrable	improvements	in	survival	for	childhood	cancer	in	resource-constrained	settings,	we	next	examine	the	cost	and	cost-effective	interventions	for	managing	childhood	cancers	in	LMICs.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
SECTION	3:	THE	OPPORTUNITY	–	COST-EFFECTIVE	SOLUTIONS	FOR	CHILDHOOD	
CANCERS		
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Competing	health	priorities	and	limited	resources	mean	that	policymakers	in	LMICs	must	set	priorities	in	order	to	allocate	the	available	resources,	including	for	childhood	cancers.			Multiple	factors	must	be	taken	into	account	when	setting	priorities	in	health	systems,	including,	the	values	of	citizens	and	policymakers,	the	burden	of	disease	and	risk,	the	expected	goals	and	outcomes,	equity,	the	efficiency	effectiveness	and	responsiveness	of	services	to	deliver	services,	and	the	cost	and	cost-effectiveness	of	interventions.128	However,	whatever	the	criteria	used	for	priority	setting,	a	clear,	transparent	and	deliberative	process	should	inform	decision-making.129		
Cost	and	cost-effectiveness	of	treatments	for	childhood	cancers		To	date,	few	studies	have	examined	the	cost	and	cost-effectiveness	of	childhood	cancer	treatments.	A	systematic	review	undertaken	in	2012,	which	analysed	cost-effectiveness	of	treatments	for	childhood	cancers	in	high-income	countries,	found	only	40	studies,	but	the	vast	majority	of	these	studies	had	focused	on	specific	interventions,	such	as	individual	supportive	care	measures	(e.g.	infection	management)	or	specific	aspects	of	cancer-directed	treatment	(such	as	stem	cell	transplantation).130	Even	a	smaller	number	of	studies	have	examined	costs	and	cost-effectiveness	of	interventions	for	childhood	cancers	in	LMIC	settings.	One	study,	which	suggested	that	treating	childhood	cancers	in	LMICs	should	be	cost-effective,	did	not	use	real-world	data	to	support	this	assertion.131	Other	economic	evaluation	or	costing	studies,	which	have	adopted	a	narrow	definition	of	cost,	either	examined	the	cost	of	chemotherapeutic	agents	alone,132	or	did	not	include	the	costs	of	outpatient	care133,134,135,	or	fixed	direct	costs136.	Other	studies	have	not	adequately	
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described	data	sources	or	provide	detailed	elements	of	costs.137	So	far,	only	two	methodologically	rigorous	and	comprehensive	micro-costing	studies	of	childhood	cancer	treatment	or	care	have	been	published.	One	of	these	studies	estimated	that,	in	China,	the	direct	cost	of	treating	retinoblastoma	per	patient	was	$9,442.138	The	other	study	estimated	the	direct	cost	of	treating	Burkitt	lymphoma	in	Uganda	was	$1312.139		Given	the	paucity	of	published	studies	in	LMICs	on	the	costs	and	cost-effectiveness	of	interventions	for	childhood	cancers,	we	undertook	a	multi-center	micro-costing	analysis	to	determine	the	cost	of	delivering	childhood	cancer	care.	The	methodology	is	presented	in	appendix	panel	5,	which	also	identifies	the	limitations	of	the	costing	study	(pp.	23-26).	
	The	annual	operating	cost	and	cost	per	new	diagnosis	for	each	of	the	three	LMIC	childhood	cancer	treatment	units	studied	are	shown	in	figure	5	with	further	detail	provided	in	appendix	table	2	(p	27).	Of	note,	the	ratio	of	cost	per	new	diagnosis	to	per	capita	GDP	was	remarkably	consistent	across	centers:	namely	6.5xGDP	in	Ghana,	6.8xGDP	in	El	Salvador,	and	6.3xGDP	in	Jalisco,	Mexico.	Personnel	and	pharmacy	(i.e.	chemotherapy	and	supportive	care)	represented	two	of	the	top	three	cost	items	in	all	three	centers	(figure	6).	Although	radiation	is	essential	for	the	treatment	of	some	cancers,	it	only	accounted	for	1%	of	costs	in	each	of	the	three	centres	studied.	
	
Figure	5:		Cost	of	childhood	cancer	services	per	newly	diagnosed	case	at	three	cancer	
centres	in	Ghana,	El	Salvador	and	Mexico	
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Figure	6:	Components	of	annual	budget	by	cost	in	selected	childhood	cancer	centres	
in	Ghana,	El	Salvador	and	Mexico	
	In	each	country,	the	cost	per	DALY	averted	through	cancer	treatment	in	each	centre	($1,034	in	Ghana	with	GDP	per	capita	of	$1,513	in	2016;	$1,624	in	El	Salvador	with	GDP	
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per	capita	of	$3920	in	2016,	and;	$3039	in	Mexico	with	a	GDP	per	capita	of	$8,208	in	2016)	was	cost-effective	(3	times	GDP	per	capita	income)	or	very-cost	effective	(1	times	GDP	per	capita	income).		
	The	consistency	of	this	finding	in	the	three	centres,	despite	substantial	differences	in	the	services	provided	and	the	outcomes	achieved,	highlights	an	important	aspect	of	childhood	cancer	treatment.	Historically,	improvements	in	outcomes	for	many	childhood	cancers	in	high-income	countries	have	been	achieved	through	advances	in	diagnostic	capabilities	allowing	for	refined	risk	stratification,	increases	in	treatment	intensity	for	those	with	aggressive	disease,	and	improvements	in	supportive	care	to	manage	treatment	complications.			The	steady	progression	of	costs	and	outcomes	in	Ghana,	El	Salvador	and	Mexico	suggests	that	even	with	basic	diagnostics,	low	treatment	intensity,	and	simple	supportive	care	measures,	a	proportion	of	children	with	cancer	can	still	be	cured.	For	example,	in	high-income	countries,	childhood	acute	lymphocytic	leukaemia	protocols	in	the	1980’s	demonstrated	that	with	far	less	intensive	(and	less	costly)	treatment	than	is	currently	standard	in	high-income	countries,	60-70%	of	children	achieved	long-term	survival.140	141	Similarly,	in	high-income	countries,	Burkitt	lymphoma	is	treated	with	multiple	courses	of	highly	intensive	multi-agent	chemotherapy	associated	with	numerous	treatment	complications,	long	inpatient	stays,	and	intensive	care	unit	support,	resulting	in	cure	rates	of	90%.142	However,	data	from	sub-Saharan	African	clinicians	and	researchers	indicate	that	
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with	single	agent	cyclophosphamide	and	minimal	supportive	care,	close	to	50%	of	children	can	still	be	cured.143			These	results	suggest	that	at	least	across	the	spectrum	of	resource	settings	studied	here,	a	particular	level	of	childhood	cancer	services	will	represent	a	very	cost-effective	investment.	However,	to	achieve	excellent	cure	rates	and	improved	survival	on	par	with	high-income	countries	new	investments	are	needed	in	LMICs	to	expand	access	to	effective	and	more	comprehensive	cancer	services	with	supportive	care.	Hence,	a	comprehensive	analysis	of	costs	and	benefits	of	scaling	services	for	childhood	cancer	globally	is	warranted	to	quantify	the	costs	of	such	a	scale	up	and	the	health	benefits	in	terms	of	enhanced	survival	and	life	years	saved	that	could	be	achieved	and	to	ascertain	whether	the	economic	benefits	outweigh	the	costs.		
	
	
	
	
	
	
	
	
	
SECTION	4:	COSTS	AND	HEALTH	AND	ECONOMIC	BENEFITS	OF	SCALE-UP	CHILDHOOD	
CANCER	CARE		
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	To	estimate	worldwide	costs	and	benefits	of	scale	up	of	policies	and	health	interventions	across	the	care	cascade	(from	access	to	health	services,	to	diagnosis,	referral	and	treatment)	to	manage	more	effectively	the	burden	of	childhood	cancers	globally	we	extended	the	Global	Childhood	Cancer	microsimulation	model	(appendix	panels	1	and	2,	pp.	16-19)	by	including	modules	on	costs	and	long-term	outcomes.	We	used	this	to	examine	alternative	policy	options.				To	estimate	the	global	costs	of	expanding	treatment	of	new	cancer	cases,	we	utilised	the	cost	estimates	generated	by	the	Commission	in	the	costing	studies	undertaken	by	the	Commission	in	Ghana,	El	Salvador	and	Mexico.	To	estimate	the	health	benefits	of	various	policy	and	health	interventions,	we	computed	long-term	outcomes	in	relation	to	life	expectancy	and	life	years	gained.	To	estimate	the	economic	benefits	we	estimated	future	potential	contributions	of	children	who	are	treated	successfully	and	survive	into	adulthood	to	enter	into	productive	employment.	We	then	compared	economic	benefits	to	costs	for	alternative	policy	options	and	health	interventions	to	estimate	potential	returns	to	investing	in	scale	up	of	effective	management	of	childhood	cancers	worldwide.			We	examined	the	effect	of	several	interventions	across	the	care	cascade,	both	individually	and	in	combination	(‘Comprehensive	Scale-up’	policy).		These	interventions	included	(i)	improved	access	to	primary	care	and	referral	to	specialty	care	(Access/Referral)	(ii)	social	support	services	to	reduce	treatment	abandonment	(Abandon)	(iii)	availability	of	treatment	(including	chemotherapy	drugs	for	a	given	regimen,	access	to	radiotherapy,	
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access	to	surgical	services)	and	improvements	in	quality	of	care	(Treatment),	and	(iv)	concurrent	implementation	of	all	interventions	((i)-(iii))	together	(Comprehensive	Scale-up).		We	assumed	that	quality	of	care,	which	depends	on	a	functioning	health	system	with	supportive	services	(e.g.,	nursing	standards,	integrated	referral,	and	record-keeping)	and	facility-level	activities	(e.g.,	infection	control	and	nutritional	support),	affects	survival.		Recognizing	that	scale-up	of	interventions	will	take	time	to	implement	in	each	country,	we	assumed	that	for	all	the	health	interventions	examined,	country-specific	model	parameters	would	increase	linearly	between	2020	and	2030	to	converge	with	the	mean	value	among	all	63	high-income	countries	(mean	values	based	on	cancer-case	weighted	estimates).			Figure	7	shows	the	parameter	values	for	low-income	countries,	low-middle-income	countries,	upper-middle-income	countries	and	high-income	countries	for	chemotherapy,	radiotherapy,	and	surgery	for	children	that	require	a	particular	modality,	(model	parameters	are	specified	inputs	that	govern	processes	in	the	model.		Because	we	use	a	Bayesian	approach	these	are	considered	random	variables	and	are	not	known	which	certainty,	but	follow	a	probability	distribution	that	is	summarized	in	the	figures).	The	mean	values	of	the	model	parameters	for	the	health	interventions	with	95%	uncertainty	intervals	are	shown	in	appendix	table	3	(p	28).	
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Figure	7:	Mean	values	of	the	model	parameters	for	health	interventions	for	countries	
by	World	Bank	Income	Group			
			Using	the	Global	Childhood	Cancer	microsimulation	model	and	the	projected	‘pathway	to	scale-up’,	as	described	above	and	depicted	in	Figure	7,	we	simulated	alternative	scenarios	of	scaling	up	interventions	either	‘alone’	or	‘all	combined’	to	estimate	the	potential	effect	in	reducing	the	global	number	of	childhood	cancer	deaths	and	improving	global	childhood	
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cancer	survival.	We	incorporated	country-specific	WHO	life	tables144,145	to	account	for	background	mortality	rates,	and	assumed	that	sex-specific	and	age-specific	mortality	rates	would	decline	between	2015	and	2030	(based	on	the	average	annual	percentage	reduction	achieved	between	2000	and	2016).	The	model	also	incorporated	excess	late	mortality	risk	among	childhood	cancer	survivors.	After	achieving	initial	disease	cure,	childhood	cancer	survivors	continue	to	face	health	risks	related	to	their	original	cancer	diagnosis	and	treatment.	We	therefore	assumed	that	survivors	continue	to	face	excess	late	mortality	risks	in	addition	to	country-specific	background	mortality	risks.146,147		 	
Health	benefits	of	scaling	health	interventions	globally	to	manage	childhood	cancers	We	present	in	Figure	8	the	projected	effect	on	deaths	and	survival	globally	by	each	intervention	along	the	care	cascade	and	all	interventions	combined.	When	scaled	up	as	a	stand-alone	intervention	increased	access	to	primary	care	and	referral	(Access/Referral)	is	projected	to	avert	905,117	deaths	(95%	UI,	728,835	to	1,104,700),	improved	social	support	services	to	reduce	treatment	abandonment	(Abandon)	237,641	deaths	(95%	UI,	150,591	to	367,746),	and	expanded	treatment	availability	with	improved	quality	of	care	(Treatment)	2,020,000	(95%	UI,	11,715,800	to	1,715,800)	childhood	cancer	deaths	between	2020	and	2050	(figure	8	and	table	7).			However,	the	effect	is	substantially	magnified	with	Comprehensive	Scale-up	areas	when	these	three	interventions	are	combined	and	scaled	up	simultaneously.	In	that	situation	an	estimated	6,235,100	(95%	UI	5,547,800	to	7,053,900)	deaths	could	be	averted	in	children	with	cancer	(56.1%	of	total	deaths;	95%	UI,	53.6%	to	58.4%)	between	2020	and	2050.	This	
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figure	is	3-fold	greater	than	what	could	be	achieved	with	expanding	treatment	availability	with	improved	quality	of	care	alone	(figure	8	and	table	7),	and	it	indicates	the	inter-dependent	and	sequential	nature	of	the	care	cascade.			
Figure	8:	Projected	effect	of	scaling	up	interventions	individually	and	in	combination	
on	global	childhood	cancer	deaths	and	overall	survival	for	all	childhood	cancers	
(2020-2050)	
	
	
	
Table	7:	Projected	total	number	of childhood	cancer	deaths	averted	between	2020	
and	2050,	and	life-years	gained	–	lifetime			
Income	
Group	
Intervention	
Scenario	
Childhood	Cancer	Deaths	Averted	
between	2020	and	2050	(95%	UI)	
Projected	Life	Years	Gained	
(Lifetime),	millions	(95%	UI)	
Number	 Percent	 Undiscounted	 Discounted	(3%)	
Global	
		
Access/Referral	 905117	(728835-1104708)	 8.2%	(6.7%-9.8%)	 52.22	(42.79-63.11)	 15.22	(12.61-18.21)	Abandon	 237461	(150591-367746)	 2.1%	(1.3%-3.3%)	 12.05	(7.76-18.72)	 3.39	(2.17-5.3)	Treatment	 2020167	(1715794-2360370)	 18.2%	(15.9%-20.6%)	 102.25	(87.3-119.24)	 28.21	(24.07-32.79)	Comprehensive	 6235086	(5547779-7053927)	 56.1%	(53.6%-58.4%)	 318.4	(284.21-359.65)	 87.93	(78.74-99.08)	
LIC	
Access/Referral	 97975	(61543-152146)	 3.0%	(1.9%-4.6%)	 6.51	(4.62-9.34)	 2.02	(1.48-2.79)	Abandon	 61915	(34689-100701)	 1.9%	(1.1%-3%)	 3.09	(1.77-5.07)	 0.86	(0.5-1.41)	
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		The	substantially	larger	effect	of	Comprehensive	Scale-up,	compared	with	scaling	up	each	intervention	separately	along	the	care	cascade,	was	consistent	for	countries	in	all	World	Bank	income	groups.	The	health	benefits	of	comprehensive	scale-up	of	interventions,	in	terms	of	reduction	in	the	number	of	childhood	cancer	deaths,	are	projected	to	be	greatest	in	lower-middle-income	countries,	followed	by	low-income	countries.	In	contrast,	the	greatest	improvement	in	5-year	survival	is	projected	for	low-income	countries	(figure	9	and	table	7).		The	model	also	projected	improvements	among	high-income	countries,	
Treatment	 558863	(442909-700484)	 17.2%	(14%-20.5%)	 27.61	(22-34.59)	 7.51	(5.99-9.37)	Comprehensive	 1951183	(1666625-2330863)	 60.0%	(56.9%-62.8%)	 98.15	(83.82-117.31)	 26.68	(22.89-31.79)	
LMIC	
Access/Referral	 533115	(385111-711422)	 8.8%	(6.4%-11.5%)	 30.18	(22.49-39.66)	 8.86	(6.69-11.53)	Abandon	 127837	(58023-237512)	 2.1%	(0.9%-4%)	 6.35	(2.92-11.81)	 1.81	(0.83-3.38)	Treatment	 1150757	(925912-1407416)	 18.9%	(15.6%-22.1%)	 57.67	(46.4-70.98)	 16.07	(13.07-19.68)	Comprehensive	 3504948	(2973584-4079867)	 57.5%	(54.8%-59.7%)	 177.25	(150.64-205.99)	 49.46	(42.28-57.15)	
UMIC	
		
Access/Referral	 257255	(193174-344189)	 16.8%	(13.9%-20.1%)	 14.56	(10.87-19.54)	 4.08	(3.06-5.47)	Abandon	 43457	(16547-85437)	 2.9%	(1.1%-5.7%)	 2.37	(0.89-4.76)	 0.65	(0.25-1.29)	Treatment	 294053	(217402-378494)	 19.2%	(14.3%-23.9%)	 16.04	(11.77-20.83)	 4.39	(3.25-5.65)	Comprehensive	 739317	(615884-879019)	 48.3%	(45.7%-50.7%)	 40.73	(33.62-48.76)	 11.18	(9.3-13.34)	
HIC	
		
Access/Referral	 16772	(11737-22639)	 7.2%	(5%-9.6%)	 0.97	(0.68-1.32)	 0.27	(0.19-0.36)	Abandon	 4252	(2704-6156)	 1.8%	(1.2%-2.6%)	 0.24	(0.15-0.35)	 0.06	(0.04-0.09)	Treatment	 16494	(14027-19381)	 7.1%	(5.9%-8.4%)	 0.94	(0.8-1.11)	 0.25	(0.21-0.29)	Comprehensive	 39637	(33012-47100)	 17.1%	(14%-19.8%)	 2.27	(1.9-2.71)	 0.61	(0.51-0.73)	
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where	variability	in	death	rates	and	survival	exist.	This	improvement	observed	in	high-income	countries,	where	variability	in	death	rates	and	survival	does	exist,	but	these	gains	are	comparatively	very	small,	since	the	model	assumes	that	countries	performing	worse	than	the	average	for	high-income	countries	would	converge	to	the	mean	death	rates	and	survival	levels	in	high-income	countries	between	2020	and	2030.	
	
Figure	9:	Projected	effect	on	comprehensive	scale-up	on	childhood	cancer	deaths	
and	overall	survival	in	countries	by	World	Bank	income	group	
	
	When	excess	mortality	risks	are	considered,	the	model	estimates	for	the	projected	number	of	life	years	gained	showed	similar	results	to	those	for	averted	childhood	cancer	deaths.	Comprehensive	scale-up	had	by	far	the	greatest	effect	globally	and	in	each	World	Bank	country	income	group	(table	7).			
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The	results	show	that,	globally,	the	number	of	undiscounted	life	years	gained	was	an	estimated	318.4	million	(95%	UI,	284.2	to	359.7	million)	for	Comprehensive	Scale-up.	This	figure	exceeds	the	total	number	of	life	years	gained	for	each	individual	intervention	is	implemented	separately	and	the	effects	combined	(166.5	million	life	years	gained	(95%UI,	137.2	to	201.0	million)).	Results	were	largely	unchanged	if	background	mortality	rates	remained	constant	at	current	2016	levels	(appendix	table	4,	p	29).			
Costs	and	economic	benefits	of	scaling-up	health	interventions	globally	to	manage	
childhood	cancers	To	estimate	global	costs	of	scaling-up	the	health	interventions	required	to	manage	childhood	cancers	effectively,	we	used	the	cost	data	generated	in	the	study	undertaken	by	the	Commission	in	Mexico,	Ghana	and	El	Salvador.	Based	on	these	cost	data,	we	assumed	that	the	average	treatment	costs	per-cancer-case-diagnosed	was	equivalent	to	7-times	GDP	per	capita	income	as	a	proxy	for	costs	associated	with	Comprehensive	Scale-up.	This	proxy	cost	for	scale-up	represents	a	conservative	estimate	based	on	the	correlation	between	GDP	per	capita	income	and	the	observed	average	costs	required	to	maintain	a	childhood	cancer	treatment	unit	in	a	low-income	country	and	a	middle-income	country.		To	estimate	the	economic	benefits	associated	with	Comprehensive	Scale-up,	we	used	the	human-capital	approach148	149	and	the	value-of-life-years	approaches36	(also	called	the	full-income	approach).	For	both	methods,	we	used	GDP	to	estimate	the	economic	gains.	In	the	human	capital	approach,	the	economic	value	of	a	life	saved	is	based	on	a	person’s	economic	contribution.	Based	on	the	World	Bank	definition	of	working	population	(adjusted	to	
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reflect	that	some	children	diagnosed	with	cancer	before	age	14	may	still	be	in	treatment	during	adolescence)150,	we	assumed	that	a	child	who	survived	cancer	would	contribute	to	1-times	the	GDP	per	capita	starting	at	age	18	and	until	age	64	(or	death,	whichever	occurs	first).		The	full-income	approach,	which	accounts	for	the	societal	benefits,	recognizing	the	intrinsic	societal	value	of	an	intervention,	even	if	the	recipient	is	no	longer	able	to	contribute	to	the	workforce,	was	based	on	2.3-times	the	GDP	per	person	in	a	given	year,	consistent	with	The	Lancet	Commission	on	Global	Health	2035.36	As	an	upper	bound,	we	used	3-times	GDP,	based	on	WHO-CHOICE	(Choosing	Interventions	that	are	cost-effective)	methodology	developed	by	the	WHO	Commission	on	Macroeconomics	and	Health	as	the	valuation	metric.151	All	GDP	estimates	were	based	on	the	International	Monetary	Fund	data	between	2015	and	2023,152	and	projected	to	2030	based	on	projections	of	the	average	percentage	growth	between	2015	and	2023	(with	a	minimum/maximum	GDP	growth	rate	of	8%	to	keep	projections	consistent	with	historical	and	anticipated	trends).			Figure	10	(a)	shows	the	cumulative	treatment	costs	and	productivity	gains	associated	with	Comprehensive	Scale-up	between	2020	and	2050	for	all	childhood	cancers.	Projected	global	cumulative	treatment	costs	(discounted)	with	Comprehensive	Scale-up	amount	to	$17.3	billion	(95%	UI	(16.9-17.6)	in	2020,	$228.8	billion	(95%	UI	220.7-237.0)	by	2030	and	$594.4	billion	(95%	UI	563.1-626.7)	by	2050	(appendix	table	5,	p	30).		We	discounted	both	costs	and	benefits	(as	measured	by	life	years	gained	which	were	then	used	to	measure	future	productivity	gains)	using	the	same	discount	rate	(individuals	prefer	to	have	benefits	
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now	and	incur	costs	in	the	future	-	time-preference,	which	reflects	the	discount	rate).	As	costs	and	benefits	are	realised	at	different	times	discounting	is	used	to	state	both	costs	and	benefits	in	terms	of	their	net	present	value.	While	treatment	costs	are	incurred	at	time	of	diagnosis	for	each	incident	cancer,	productivity	gains	accrue	only	once	a	child	survives	cancer	and	reaches	age	18.	This	leads	to	a	lag	in	time	before	cumulative	productivity	gains	are	projected	to	exceed	treatment	costs.	However,	global	cumulative	productivity	gains	do	exceed	cumulative	costs,	which	is	projected	to	occur	globally	in	2043	at	2.3xGDP,	or	by	2045	if	global	treatment	costs	and	productivity	gains	are	discounted	by	3%	(figure	10	(a)).			Figure	10	(b)	and	appendix	table	5	(p	30)	show	discounted	results	by	country	income	group.	Projections	show	that	cumulative	productivity	gains	exceed	cumulative	costs	in	lower-middle	income	countries,	middle-income	countries	and	high-income	countries	at	some	point	during	the	period	2020-2050,	and	after	2050	for	low-income	countries.			
	
Figure	10:	Projected	cumulative	costs	and	productivity	gains	with	global	
Comprehensive	Scale-up	of	health	interventions	for	all	childhood	cancers	
Figure	10	(a)	Global	(Undiscounted	and	Discounted) 
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Figure	10	(b)	By	country	income	groups	(Discounted)	
	
	
Estimates	of	net	economic	benefits	and	return	on	investment	for	global	
Comprehensive	Scale-up	of	health	interventions	for	all	childhood	cancers		To	estimate	the	return	on	investment	for	global	Comprehensive	Scale-up	of	health	interventions	for	childhood	cancers,	we	compared	global	cumulative	treatment	costs	with	the	global	lifetime	productivity	gains	among	survivors	for	all	cancers	diagnosed	in	children	between	2020	and	2050	(both	costs	and	productivity	were	discounted	at	3%	(appendix	table	6	pp.	31-32).			
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Using	the	2.3-times	GDP	valuation	metric,	we	estimate	global	lifetime	productivity	gains	of	$2,580	billion	(95%	UI,	$2,444.0	to	$2,726	billion).	This	is	four	times	greater	than	the	cumulative	treatment	costs	of	$594.4	billion	(95%	UI,	$563.1	to	$626	billion).	This	suggests	a	a	net	benefit	of	$1,986.1	billion	(95%	UI,	1884	to	2101),	and	a	net	return	on	investment	of	more	than	3-times	–	i.e.	for	each	$1	invested	in	improving	care	of	childhood	cancers	a	net	return	of	$3	is	realised	in	the	period	2020-2050.				Results	by	World	Bank	country	income	group	(figure	11)	show	that	in	each	country	income	group	the	global	lifetime	productivity	gains	exceed	cumulative	treatment	costs.	This	would	generate	very	substantial	net	benefits	and	a	positive	net	return	on	investment.			
Figure	11:	Lifetime	cumulative	treatment	costs,	productivity	gains	and	net	benefits	
of	comprehensive	scale	up	for	all	childhood	cancers	diagnosed	in	2020-2050	
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The	projections	with	the	Comprehensive	Scale-up	scenario	assumed	100%	scale	up	of	the	three	groups	of	health	interventions	for	childhood	cancers	along	the	care	cascade	to	reach	the	high-income	country	mean	targets.	In	some	country	settings,	100%	scale	up	may	be	challenging	due	to	health	system	weaknesses.	Therefore,	we	varied	the	percentage	of	scale-up	from	0%	(no	interventions)	to	100%	(Comprehensive	Scale-up).	We	then	estimated	net	benefits	realised	from	productivity	gains	at	1xGDP,	2.3x	GDP	and	3xGDP	based	on	the	values	used	in	the	literature36	(appendix	table	7,	pp.	33-34).			The	results	show	that	globally,	scaling-up	health	interventions	to	achieve	improvements	along	the	care	cascade	for	childhood	cancers	is	projected	to	produce	productivity	gains	that	exceed	costs	(figure	12).	This	would	lead	to	positive	net	benefits	at	all	levels	of	scale	up	(figure	13).			There	were	net	benefits	at	all	levels	of	scale	up	for	each	country	income	groups.	However,	for	low-income	countries,	where	a	scale-up	of	at	least	40%	(e.g.	all	low-income	countries	moved	40%	of	the	way	between	their	current	levels	of	health	system	performance	and	mean	high-income	country	target	levels)	would	be	required	for	lifetime	productivity	gains	to	outweigh	the	cumulative	treatment	costs	(figure	13	and	appendix	table	7,	pp.	33-34).		The	longer	time	period	and	higher	scale-up	required	in	low-income	countries	to	achieve	lifetime	productivity	exceeding	costs	is	because	workforce	productivity	is	lower	in	LIC,	which	accounts	for	some	of	this	difference,	and	where	salaries	(as	proxied	by	GDP	per	capita	income)	are	relatively	lower.		In	addition,	higher	competing	mortality	rates	in	low-income	countries	means	that	childhood	cancer	survivors	are	less	likely	to	survive	as	long	as	
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individuals	in	other	countries,	which	also	reduces	the	estimates	of	future	productivity	gains.	
Figure	12:	Lifetime	costs	and	productivity	gains	(US$	billions)	at	different	levels	of	
scale-up	(global	and	by	country	income	group)	
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Figure	13:	Net	benefit	from	investments	to	scale-up	health	interventions	for	
childhood	cancers	at	different	levels	
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Given	the	complexity	of	implementing	Comprehensive	Scale-up,	additional	costs	may	be	incurred	to	strengthen	the	health	system	over	and	above	the	costs	for	interventions	for	managing	childhood	cancers.	We	therefore	undertook	a	sensitivity	analysis	on	costs,	productivity	gains	and	net	benefits,	assuming	some	additional	health	system	costs,153	154	which	have	been	estimated	as	being	necessary	when	scaling	up	other	targeted	health	programmes	globally.	Our	projections	indicate	that	even	if	additional	costs,	equal	to	20%	of	cancer	treatment	costs	were	included	in	overall	costs,	directionally,	the	results	relating	to	benefits	with	scale	up	were	largely	unchanged	(appendix	tables	8,	9	and	10,	pp.	35-38	and	appendix	figures	1	and	2	pp.	39-40).			The	results	clearly	show	the	substantial	health	and	economic	benefits	of	comprehensive	scale	up	of	health	and	social	interventions	for	childhood	cancer	to	expand	access	to	treatment,	improve	healthcare	services,	and	reduce	abandonment.			The	economic	benefits	far	exceed	the	costs	of	scale	up	of	interventions	globally.	The	net	benefits	are	positive	in	each	country	income	groups,	and	at	all	levels	of	scale	up	in	middle-income	and	high-income	countries.	Only	in	in	low-income	countries	where	the	relevant	services	are	currently	all	but	absent,	would	a	scale-up	of	at	least	40%	or	more	would	be	required	to	achieve	a	net	economic	benefit.	The	projected	net	economic	benefits	would	be	greatest	if	interventions	are	scaled	up	in	combination	and	simultaneously.	This	underlines	the	importance	of	a	comprehensive	and	integrated	response.			
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These	results	provide	a	compelling	case	for	investing	in	comprehensive	scale-up	of	childhood	cancer	services.	We	next	explore	how	global	scale-up	could	be	achieved,	the	preconditions	for	success	and	the	potential	roles	and	responsibilities	of	the	main	actors	in	realising	the	goal	of	comprehensive	care	for	childhood	cancers	worldwide.																			
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SECTION	5:	SCALING	UP	COMPREHENSIVE	CARE	FOR	CHILDHOOD	CANCERS	
WORLDWIDE		There	is	a	compelling	case	for	investing	in	the	scale-up	of	diagnosis,	treatment	and	care	of	children	with	cancer.	This	would	prevent	millions	of	needless	deaths	in	children.	It	would	address	the	unacceptable	inequities	in	access	to	healthcare	and	health	outcomes	within	and	between	countries.	It	would	also	help	realise	large	economic	returns	for	countries	and	families.			However,	the	magnitude	and	the	speed	of	the	global	and	country-level	responses	to	the	global	needs	of	children	with	cancer	will	depend	on	far	more	than	the	evidence	and	health	system	capabilities.	It	will	also	require	political	will,	leadership,	understanding	of	the	models	of	care	that	can	be	scaled	up,	human	resource	capability,	and	the	availability	of	country-level	(domestic)	and	external	finances.	In	this	section	we	discuss	pathways	to	scale-up.	We	explore	suitable	service	delivery	models	for	providing	childhood	cancer	care,	how	best	to	use	existing	service	delivery	platforms	developed	in	low-income	countries	and	middle-income	countries,	how	to	expand	human	resource	capacity,	and	potential	sources	of	funding.		
	
Pathways	to	scaling	up	healthcare	services	for	childhood	cancer:	country	roadmaps,	
facility	tiers,	and	intervention	packages	Addressing	 childhood	 cancer	 requires	 the	 development	 of	 a	 specific	 framework	 that	 is	integrated	within	national	health	systems,	but	is	sensitive	to	the	unique	circumstances	that	
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define	 cancer	 in	 children,	 where	 comprehensive	 multidisciplinary	 care	 along	 the	 entire	continuum	of	care	is	critical.			Context	adaptation	of	guidelines	for	diagnosis	and	treatment	provides	an	opportunity	 for	policymakers	to	align	the	guidelines	with	the	available	resources	and	country	priorities	and	to	 plan	 resource-appropriate	 cancer	 care	 programmes	 for	 children.155,156	 The	implementation	of	these	tailored	approaches	will	require	the	development	and	validation	of	levels	of	care	that	accurately	reflect	the	status	of	regions,	countries	and	paediatric	oncology	units	of	interest.5,157,158			The	Commission	explored	this	concept	 further,	 to	develop	a	model	of	 ‘country	roadmaps’	and	‘facility	tiers’	with	integrated	service	packages	for	the	development	and	implementation	of	 childhood	 cancer	 care.	 Other	 health	 areas,	 such	 as	maternal	 and	 neonatal	 health,	 and	trauma	medicine	have	successfully	developed	and	implemented	care	models	based	on	levels	of	 care,159,160	 to	 show	 the	 correlation	 of	 those	 models	 with	 quality	 indicators	 and	outcomes.161,162,163				To	 develop	 a	 model	 of	 ‘country	 roadmaps’	 and	 ‘facility	 tiers’	 with	 integrated	 service	packages,	the	Commission	used	a	modified	Delphi	Process	with	three	rounds	of	surveys	to	derive	consensus	on	the	care	that	could	be	provided	at	each	level	and	the	country	capabilities	needed	to	provide	such	care.	The	respondents	to	the	Delphi	study	included	commissioners	and	 multidisciplinary	 experts	 (including	 paediatric	 oncologists	 and	 nurse	 specialists)	representing	all	WHO	regions	and	World	Bank	income	groups.	In	addition,	to	contextualize	
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the	 scoping	 review	 and	 complement	 the	 Delphi,	 working	 groups	 inclusive	 of	multidisciplinary	providers	experienced	with	intervention	needs	in	LMICs	met	in	person	and	online	over	a	period	of	more	than	18	months	to	review	evidence	and	refine	key	concepts	for	facility	and	country	tiers,	and	childhood	cancer	packages. 		Considering	 varied	 capabilities	 in	 countries	 the	 Commission	 identified	 country	 tiers	 and	identified	steps	to	progressively	transition	to	higher	capabilities	while	strengthening	health	systems	in	the	process	(panel	7).			
Panel	7:	Developing	tiers	of	capability	for	childhood	cancers	and	strengthening	health	
systems	Not	all	countries	are	equally	equipped	to	address	 the	burden	of	childhood	cancer,	but	all	countries	must	 consider	how	 they	 can	 improve	 the	quality	 of	 care	 and	population-based	outcomes	 for	 children	 with	 cancer	 within	 their	 resource	 constraints.	 The	 Commission	considered	that	elements	of	a	health	system	to	guide	the	definition	of	country	tiers	in	global	pediatric	oncology.	Defining	country	capabilities	can	help	develop	models	for	health	system	strengthening	of	greater	 impact	 than	achievable	by	 focusing	exclusively	on	strengthening	individual	facilities;	better	understand	the	country’s	capacity	and	the	country's	readiness	to	address	 and	 improve	 population-based	 childhood	 cancer	 outcomes;	 better	 evaluate	 and	benchmark	 population-based	 childhood	 cancer	 outcomes;	 and	 understand	 the	 country’s	readiness	 to	 have	more	 of	 its	 facilities	 ascend	 through	 facility	 tiers.	 Attentiveness	 to	 the	country	capabilities	can	improve	a	facility’s	understanding	of	its	role	in	the	health	system	and	help	 foster	 communication,	 integration,	 and	 common	purpose	between	 facilities	 and	
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with	 policy	makers	 and	 government	 agencies,	 and	 prioritize	areas	 in	 which	 a	 facility	 or	network	of	facilities	and	its	personnel	should	participate	in	advocacy.		The	 ‘steps’	 illustrate	 how	 progressive	 acquisition	 of	 these	 capabilities	 and	 stepwise	implementation	of	policy	enablers,	such	as	effective	stewardship	and	governance,	adequate	financing,	delivery	of	services	with	evidence-based	interventions	and	essential	medicines,	equitable	 access	 to	 care	 and	health	 information	 systems	with	 suitable	vital	 statistics	 and	cancer	 registries	 that	 include	 childhood	 cancer,	 can	 accelerate	 progress	 by	 easing	 the	facilities’	delivery	of	childhood	cancer	care	and	monitoring	and	evaluation	of	progress.	The	proposed	 country	 tiers	model	 needs	 to	 be	 interpreted	 as	 a	 roadmap	 towards	 a	 goal;	 the	framework	should	serve	as	a	consensus-derived	step-by-step	guide	of	health	system	policy	enablers	needed	for	optimal	delivery	of	childhood	cancer	services	in	a	given	country,	with	downstream	effects	on	facility	capabilities	(figure	14).		
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Figure	14:	Country	roadmap	to	guide	acquisition	of	capabilities	for	childhood	cancer	care	
		Context	adaptation	of	diagnostic	and	treatment	guidelines	requires	a	detailed	definition	of	the	 capabilities	 of	 the	 center	 where	 care	 is	 delivered.	 While	 the	 focus	 of	 guideline	development	 has	 emphasised	 guidance	 for	 treatment	 decisions	 based	 on	 facility	 level	resources,	 interconnectedness	 among	 facilities	 as	 a	 strategy	 to	 increase	 capabilities	 and	treatment	opportunities,	or	 to	 improve	outcomes	has	not	been	explored.	 In	the	proposed	networked-tiers	model,	while	it	is	understood	that	not	all	facilities	are	equally	equipped	to	diagnose	and	treat	all	childhood	cancers,	all	paediatric	oncology	units	must	consider	their	scope	and	role,	determine	how	they	can	improve	the	quality	of	care	and	outcomes	for	all	children	with	cancer	within	the	resource	constraints	of	their	facility,	and	how	to	establish	formal	 collaborations	 with	 other	 facilities	 in	 the	 country	 or	 region.	 Each	level	in	 the	framework	must	 provide	 the	 highest	 quality	 care	 possible	 for	 their	 scope	 and	 meet	 all	
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capabilities	defined	in	the	preceding	(lower)	levels.	Lower	level	facilities	have	unique	care	delivery	 and	 supportive	 care	 functions;	 they	 should	 not	 be	 perceived	merely	 as	 referral	centers	 to	 higher	 tier	 facilities.	Higher	 facilities	 have	 unique	 education,	 consultative,	 and	collaborative	functions;	they	are	not	merely	referral	centers	to	lower	tier	facilities	(figure	15).		Figure	15:	Desirable	capabilities	at	each	level	of	care	for	childhood	cancers	
		The	 Delphi	 study	 also	 helped	 to	 define	 the	 essential	 care	 packages	 most	 important	 for	prioritization	at	a	national	level	for	sustainable	paediatric	cancer	care,	with	integration	in	the	 country	 roadmap	 and	 facility	 tier	models.	 Defining	 care	 packages	 at	 a	 national	 level	allows	priority	setting	for	effective	care	and	investment,	promoting	enhanced	functioning	
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and	ultimately	performance	of	the	health	system	to	achieve	a	patient-level	positive	impact	that	can	be	sustained.			The	Sustainable	Pediatric	Cancer	(SuPer)	Packages	considered	four	intervention	pathways:	diagnosis,	treatment,	treatment	completion,	and	integrated.	The	SuPer	package	framework	included	three	overarching	package	sets	connected	to	the	proposed	country	roadmap	and	facility	tiers.	First,	a	Core	Sustainable	Pediatric	Cancer	(SuPer)	Package,	is	expected	to	apply	in	 most	 to	 nearly	 all	 settings,	 and	 which	 encompasses	 pediatric	 cancer	 needs	 broadly.	Second,	an	Advanced	SuPer	Package,	is	expected	to	apply	in	many	settings,	and	is	typically	introduced	 after	 the	 interventions	 in	 the	Core	Package.	 Third,	 a	Maximal	 SuPer	Package,	expected	to	currently	apply	in	a	minority	of	settings,	typically	introduced	after	interventions	outlined	in	the	Advanced	Package,	and	is	most	dependent	on	resource	and	capability	levels,	diagnoses,	and	outcomes.			This	SuPer	Package	framework	is	outlined	in	figure	16.		Given	the	overlapping	and	nuanced	contextual	differences,	 it	was	 intentional	 for	 the	boxes	not	 to	exactly	 line	up	horizontally	with	 the	 facility	 levels.	 For	 instance,	 while	 the	 Core	 SuPer	 Package	 should	 be	 feasible	including	 in	settings	with	 low	resource	capabilities	(Level	1	Childhood	Cancer	Treatment	Facilities)	 and	 starting	 in	 countries	 at	 Roadmap	 Step	 1,	 the	 Advanced	 SuPer	 Package	 is	typically	feasible	starting	only	in	settings	with	moderate	to	high	resource	capabilities		(Level	2	 to	3	Facilities)	and	 typically	 corresponding	 to	 countries	 that	are	at	Roadmap	Step	2	or	above.	The	Maximal	SuPer	Package	is	typically	considered	feasible	by	settings	with	maximal	
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resource	 capabilities	 (a	 few	 select	 Level	 3	 and	 mostly	 Level	 4	 Facilities),	 and	 typically	corresponding	to	countries	that	are	at	Roadmap	Step	3	or	above	(figure	16).		These	 three	 illustrative	 care	 packages	 offer	 an	 indicative	 framework	 for	 governments	 to	identify	and	contextualize	opportunities	for	scale-up,	aligned	to	the	tier	system	developed	for	facilities	and	the	country	roadmaps.			
Figure	 16:	 Sustainable	 Paediatric	 cancer-specific	 framework	 for	 essential	
intervention	packages	[SuPer	Packages	Framework]	
		As	 countries	have	a	heterogeneous	mix	of	 childhood	cancer	 treatment	 facility	 levels,	 it	 is	helpful	 to	 consider	 both	 facility	 levels	 and	 country	 roadmaps	 to	 contextualize	 how	 care	packages	could	be	developed.	The	Commission	noted	that	the	facility	tiers	and	the	packages	
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provided	should	be	sensitive	to	the	country	roadmap	and	each	country	should	articulate	a	model	 that	 facilitate	 progression	 in	 a	 stepwise	 manner	 as	 capabilities	 are	 developed	 to	manage	 different	 childhood	 cancers	 (figure	 17).	 Part	 of	 the	 stepwise	 approach	 is	 also	intended	 to	 highlight	 that	 more	 is	 not	 necessarily	 better.	 More	 advanced	 interventions	without	the	appropriate	health	system	context	could	unintentionally	reduce	patient	survival	and	compromise	health	system	efficiency	and	effectiveness	because	of	increased	treatment	related	morbidity,	 for	example	undertaking	complex	surgery	or	bone	marrow	transplant,	without	appropriate	infrastructure	for	operation	planning,	blood	transfusion,	and	infection	control.			These	 capabilities	 can	 be	 developed	 in	 a	 stepwise	 manner	 in	 countries	 with	 differing	resources,	with	a	pathway	for	realization	of	these	capabilities	over	time	to	provide	services	of	increasing	complexity	and	resource	intensity	to	treat	different	childhood	cancers	(figure	17)	as	resources,	competences	and	policies	permit.		
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Figure	17:	Capabilities	needed	 to	provide	 interventions	 of	 differing	 complexity	 for	
childhood	cancers	
		Through	the	Delphi	process,	the	Commission	also	explored	how	networked	models	of	care	could	be	developed	to	facilitate	access	to	best	quality	care	possible	within	a	health	system,	as	proposed	by	other	disciplines.164,165			Since	most	 countries	 have	more	 than	 one	 paediatric	 oncology	 facility	 and	 resources	 are	always	limited.	Hence,	there	is	strong	argument	for	greater	integration	between	facilities	to	strengthen	health	systems	and	ensure	optimal	delivery	of	equitable	and	patient-centered	care.	 In	 countries	with	 only	 one	pediatric	 oncology	 care	 facility,	 improvements	 in	 health	
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system	 can	 result	 from	 greater	 integration	 between	 paediatric	 oncology	 facilities	 and	‘referral	base’	facilities.	
	
Alignment	of	scaling	of	services	for	childhood	cancers	with	universal	health	coverage	UHC	is	the	top	priority	for	WHO.166		Expansion	of	UHC	offers	a	unique	opportunity	for	LMICs	to	expand	care	for	children	with	cancer.	Funding	for	expansion	of	UHC	will	mainly	come	from	domestic	sources.	In	health	systems	that	are	funded	predominantly	from	taxation,	cancer	care	could	be	publicly	funded	from	government	health	budget	as	part	of	the	general	health	services,	provided	either	by	public	providers	or	foundations.			In	low-income	countries,	where	there	are	fiscal	space	constraints,	philanthropic	funding	and	external	financing	through	development	assistance	for	health	could	be	pooled	and	channeled	to	healthcare	budgets	to	augment	(but	not	displace)	government	funding.	In	countries	where	healthcare	funding	is	a	mixture	of	government	funding	and	health	insurance,	publicly	financed	health	insurance,	funded	through	non-contributory	schemes	resources	from	the	government	budget,	should	be	used	to	cover	an	essential	benefits	package	that	incorporates	care	for	children	with	cancer.	Children	with	cancer	should	be	exempted	from	payment	for	care.	This	is	crucial	to	ensure	that	the	child’s	family	is	protected	against	financial	risk.			The	essential	package	of	interventions	and	services	for	childhood	cancer	could	be	gradually	expanded	as	financing	and	health	system	capabilities	expand	to	extend	UHC,	and	out-of-pocket	payments	are	eliminated	to	provide	financial	risk	protection	and	to	stop	the	
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abandonment	of	treatment	and	care.		It	is	important	that	essential	package	of	interventions	benefits	all	children	equally.		Research	from	Colombia	suggests	that	disparities	in	mortality	and	5-year	survival	in	children	with	cancer	persist	even	with	UHC	if	the	essential	service	packages	differ	for	populations.	Children	who	have	access	to	greater	healthcare	benefits	have	better	health	outcomes	compared	to	those	with	less	benefits	and	those	who	are	uninsured.167				Incorporation	of	treatment	and	care	for	childhood	cancers	within	essential	benefits	packages	in	health	insurance	funded	systems,	or	as	a	core	service	in	government-funded	health	systems,	is	a	critically	important	step	if	the	global	expansion	of	childhood	cancer	services	is	to	be	achieved.	This	strategy	of	alignment	and	integration	is	fully	aligned	with	the	recommendations	of	the	WHO	Consultative	Group	on	Equity	and	Universal	Health	Coverage.	The	recommendation	of	this	group	for	the	criteria	to	use	in	expanding	UHC	included	cost-effectiveness,	giving	priority	to	the	worse	off,	financial	risk	protection,	eliminating	out-of-pocket	payments,	and	ensuring	inclusion	of	priority	groups.168		
	
Use	of	existing	health	system	platforms	to	scale	services	for	children	with	cancer	Expansion	of	essential	packages	of	interventions	for	children	with	cancer	must	be	fully	integrated	within	health	system	structures	and	use	existing	platforms.	This	defined	in	DCP3	as	“logistically	related	delivery	channels”.169			The	Commission	findings	show	that	one	of	the	major	challenges	in	improving	the	management	of	childhood	cancers	on	a	global	scale	is	interruption	of	care	at	various	points	
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along	the	care	pathway,	due	to	health	system	weaknesses	and	poor	integration	of	care.	Removing	these	barriers	along	the	care	pathway	will	require	development	of	integrated	care	networks	that	seamlessly	combine	community-level	services,	health	centres,	first-level	hospitals,	and	referral-	and	specialty-hospitals.		These	platforms	for	scale-up	will	enable	the	development	of	integrated	care	networks	for	the	management	of	childhood	cancers	and	help	reduce	interruptions	of	care	in	the	care	pathway.	Such	networks	should	also	help	to	optimise	use	of	available	capacity	for	diagnostic	imaging,	surgery,	radiotherapy,	pathology	and	laboratory	medicine	services,	infection	control,	transfusion	services,	and	palliative	care,	which	is	particularly	lacking	in	most	LMICs.170		
	
Developing	human	resource	capacity	for	scale	up	The	global	shortage	of	health	professionals,	especially	in	LMICs,	is	one	of	the	major	barriers	to	expanding	services	for	childhood	cancers.	Shortage	of	well-trained	health	professionals	is	also	a	major	barrier	to	the	effective	and	safe	operation	of	available	capacity.	New	approaches	are	needed	to	meet	these	shortfalls	in	human	resources.			The	exact	workforce	needs	will	vary,	depending	on	the	current	burden	of	cancer,	the	distribution	of	healthcare	providers,	the	accessibility	of	alternative	care	settings,	public	demand	and	expectations	and	utilisation	of	different	levels.	The	Commission	considered,	through	the	Delphi	process,	a	‘reasonably	achievable’	target	in	LMICs	for	the	number	of	newly	diagnosed	paediatric	cancer	patients	that	could	be	cared	for	each	year	by	a	physician	with	specific	training	for	management	of	childhood	cancer.	The	consensus	for	a	reasonable	number	was	50	(approximately	one	new	patient	per	week).		Many	respondents	provided	
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current	examples	from	LMICs	that	in	practice	the	current	ratio	staffing	is	typically	more	than	100	new	children	with	cancer	diagnosed	per	physician	each	year	and	that	multi-disciplinary	teams	were	lacking.				The	Commission	strongly	noted	the	need	to	develop	multidisciplinary	teams	and	specialised	training	for	the	health	workforce	dedicated	to	providing	childhood	cancer	care	(appendix	pp.	41-44).		Workforce	needs	may	be	different	in	some	settings	where	only	a	few	cancer	types	are	treated.	For	example,	treatment	of	childhood	leukemia	may	not	require	complex	surgical	services.	Initial	management	of	two-third	of	patients	with	solid	malignancies,	including	highly	curable	conditions	such	as	Wilms	tumours,	is	feasible	even	in	resource-limited	settings.171,172	However,	more	advanced	capabilities	are	needed	for	the	management	of	some	solid	tumours,	with	investment	in	essential	surgical	services	and	pathology	services.173,174				While	rapid	expansion	in	the	numbers	of	health	professionals	in	the	near	future	is	not	realistic,	given	resource	constraints,	a	multi-pronged	approach	could	help	expand	the	capacity	needed	to	provide	health	services	with	optimal	use	of	the	health	workforce.			The	first	of	these	approaches	is	‘task-sharing’,	which	have	been	effectively	used	in	LMICs	to	engage	a	broader	group	of	health	professionals	in	the	provision	of	effective	healthcare	services,175,176	including	for	children,177	with	improvements	in	efficiency	and	cost	
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savings178.	The	second	is	the	use	of	new	mobile	technologies	to	improve	care	management,179	communicate	results,180	improve	attendance	at	clinics,181	and	improve	patient	self-management	for	long-term	illnesses182.	The	third	is	the	development	of	novel	competency-based	curricula,	which	use	distance	learning,	e-learning	and	mobile	digital	education	for	undergraduate,	postgraduate	and	in-service	training	of	health	professionals	to	enable.	This	can	rapidly	enable	low-cost,	efficient	and	effective	development	of	a	large	pool	of	trained	health	professionals.183,184	The	fourth	element	of	a	multi-pronged	human	resource	development	approach	is	to	introduce	incremental	licensing,	in	which	gradual	upgrades	of	responsibilities	and	competence	are	underpinned	by	on-the-job	training	and	professional	development,	with	appropriate	increases	in	incentives	and	rewards.	
	
Innovations	in	service	delivery	to	scale	services	for	children	with	cancer	Integration	of	childhood	cancer	services	with	existing	service	delivery	platforms	should	be	accompanied	with	innovations	to	develop	new	healthcare	service	models	relevant	to	LMICs.	Effective	integration	and	reduction	of	service	duplication	could	help	overcome	resource	shortages,	particularly	for	human	resources	which	is	a	major	hindrance	to	expansion	of	cancer	services,	remove	barriers	to	efficient	and	effective	care	delivery,	and	help	accelerate	adoption	of	existing	and	new	technologies.	Integration	of	strengthened	childhood	cancer	services	within	the	health	system	can	also	create	positive	synergies	to	improve	other	services,	such	as	haematology,	pathology	laboratory	medicine,	and	infection	control,	by	enhancing	quality.		
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When	developing	innovative	service	delivery	LMICs	do	not	necessarily	need	to	replicate	models	of	care	from	high-income	countries,	which	are	based	on	narrow	specialists	and	expert-led	systems	and	have	evolved	over	many	decades.	Instead,	there	is	an	opportunity	to	learn	from	innovative	delivery	models	developed	in	LMICs	for	managing	chronic	conditions185,	HIV186,187	and	tuberculosis188,189.	These	innovative	service	delivery	models	have	emphasised	the	simplification	of	care,	decentralisation	of	care	to	primary	health	centres	and	communities	with	strong	reliance	on	a	non-physician	health	workforce	(including	nurses	and	community	health	workers),	community	involvement,	peer	support	and	self-management190.	 
	
Financing	for	global	scale	up	of	healthcare	for	childhood	cancer	Global	financing	is	needed	to	catalyse	the	response	for	addressing	the	childhood	cancer	burden	and	for	the	production	of	global	public	goods,	such	as	internationally	accepted	but	contextually-sensitive	guidelines	for	diagnosis,	treatment	and	care;	research	for	the	development	of	effective	and	efficient	care	delivery	models	that	coordinate	affordable	diagnostics,	surgery,	radiotherapy,	medicines	and	palliative	care;	harmonized	norms	and	standards	for	surveillance	through	development	and	strengthening	of	cancer	registries	in	all	countries;	and,	global	data	for	comparative	analysis	and	shared	learning.191		In	most	countries,	domestic	sources	will	provide	most	of	the	funding	for	scaling	up	services	for	better	management	of	childhood	cancers.	The	sources	are	most	likely	to	be	from	public	financing	(government	budget	allocated	to	health,	or	health	insurance),	perhaps	with	complementary	financing	from	health	insurance.	
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	At	country	level,	public	financing	for	any	sector,	including	health,	is	determined	by	the	‘fiscal	space’	available	to	the	government.192	Fiscal	space	is	defined	as	“…the	availability	of	budgetary	room	that	allows	a	government	to	provide	resources	for	a	desired	purpose	without	any	prejudice	to	the	sustainability	of	a	government’s	financial	position.”193			Fiscal	space	depends	on	the	sources	of	finance	available	to	a	government	from	(i)	improved	economic	growth	that	creates	favourable	macroeconomic	conditions	for	government	budget	that	could	be	allocated	to	health	(ii)	generation	of	revenues	by	strengthening	tax	administration	in	LMICs,	where	government	revenues	from	tax	are	low,	ranging	from	10-15%	of	GDP	compared	to	30-40%	for	high	income	countries	(iii)	reprioritization	of	health	within	the	government	budget	(iv)	borrowing	from	domestic	and	international	sources	to	invest	in	health	(v)	innovative	domestic	and	international	financing,	and	(vi)	more	effective	and	efficient	allocation	of	available	health	resources.194,195			The	funding	for	childhood	cancer	services	and	UHC	will	predominantly	come	from	domestic	sources	of	financing.	Expansion	of	fiscal	space	for	health	is	therefore	critical	for	governments	in	LMICs,	if	the	goals	of	scaling-up	cancer	services	for	children	and	UHC	are	to	be	achieved.	Each	of	the	six	avenues	discussed	above	offers	potential	for	expanding	the	fiscal	space	to	enable	greater	investment	in	health,	especially	economic	growth,	new	taxes,	innovative	financing	and	reduced	waste	in	health	systems.	We	discuss	these	briefly.		
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(i)	Improved	economic	growth:		according	to	the	International	Monetary	Fund	(IMF),	LMICs	are	projected	to	achieve	economic	growth	between	2020	and	2025,196	with	potential	to	expand	the	fiscal	space	for	health.	Estimates	suggest	that	in	2015-40,	continued	growth	of	GDP,	improved	government	revenues	and	expanded	government	spending	on	health	could	help	increase	per	capita	health	by	5.3%	(UI	4.1-6.8)	each	year	in	upper-middle-income	countries,	4.2%	(UI	3.8-4.9)	in	middle-income	countries	and	1.8%	(UI	1.0-2.8)	in	low-income	countries.197		(ii)	Generation	of	revenues	by	strengthening	tax	administration:	Judicious	increase	in	taxes	is	a	potential	source	of	government	revenues	to	expand	the	fiscal	space.	In	particular,	increased	taxes	on	tobacco	and	alcohol,	which	are	highly	cost-effective	public	policies,	offer	potentially	large	revenues	for	health.	Egypt,	the	Philippines	and	Thailand	have	successfully	used	tobacco	taxes	to	generate	earmarked	funding	for	the	health	sector.198		(iii)	Reprioritization	of	health	within	government	budget:	Demonstration	of	health	and	economic	benefits	for	health	investments	could	provide	the	necessary	evidence	to	persuade	governments	to	increase	investments	in	health.		(iv)	Borrowing	from	domestic	and	international	sources:	Concessional	financing	with	low	interest	rates	and	a	generous	grace	period	for	repayments	could	be	mobilised	from	international	development	banks	to	invest	in	health.	For	interventions	that	generate	substantial	health	and	economic	benefits	and	positive	return	on	investment,	such	as	services	for	treating	childhood	cancers,	borrowing	is	justified.			
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		(v)	Innovative	financing:	A	further	potential	source	of	new	and	additional	funding	for	scaling	up	sustainable	care	for	childhood	cancers	is	innovative	financing	–	funding	mobilised	from	non-traditional	mechanisms.			In	2002,	the	International	Conference	on	Financing	for	Development	in	Monterrey,	Mexico,	identified	 innovative	 financing	as	a	promising	source	of	new	and	additional	 financing	 for	global	 health.199	 Since	 then,	 innovative	 financing	 mechanisms200	 (which	 link	 different	elements	of	the	financing	value	chain—namely,	resource	mobilisation,	pooling,	channelling,	resource	allocation,	and	implementation)	and	innovative	financing	instruments201	(used	to	mobilise	funding)	have	enabled	mobilisation	and	channeling	of	substantial	funds	for	health	programmes	 globally.	 Innovative	 financing	 (panel	 8)	 could	 help	 augment	 funding	 from	domestic	sources	to	catalyse	scale-up	of	services	for	childhood	cancer.			
Panel	8:	Innovative	financing	for	funding	investments	in	childhood	cancers		To	 date,	 three	 innovative	 financing	 mechanisms	 (which	 mobilise	 funding	 from	 multiple	sources,	 and	 pool,	 allocate	 and	 channel	 these	 funds	 health	 programmes	 in	 LMICs)	 have	reached	a	global	scale,	namely	the	Global	Fund	to	Fight	AIDS,	Tuberculosis	and	Malaria	(the	Global	Fund,	established	in	2002)202,	GAVI	(established	in	2000)203,	and	Unitaid	(established	in	2006).204	By	 June	2019,	 the	Global	Fund	had	disbursed	US$	41.4	billion	 for	HIV/AIDS,	tuberculosis,	malaria	and	health	systems,202	GAVI	had	disbursed	US$13.4	billion	for	vaccines	by	 November	 2018,203	 and	 by	 2017	 UNITAID	 had	 invested	 more	 than	 US$2	 billion,	 in	
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medicines,	 diagnostics	 and	 health	 products	 for	 HIV/AIDS,	 drug	 resistant	 tuberculosis,	malaria,	and	Hepatitis	C204.		Several	innovative	financing	instruments	have	been	developed	to	generate	and	mobilise	funds	totaling	around	US$8·9	billion	in	2002–15.201	For	example,	the	Airline	Solidarity	Levy,201	which	involves	a	small	tax	(levy)	on	airline	tickets	in	participating	countries,	has	generated	regular	funding	for	Unitaid.	Financial	transaction	taxes205,	introduced	to	reduce	excessive	speculation	in	financial	markets,	are	potentially	large	source	of	innovative	financing.	Countries,	such	as	South	Korea,	India,	Brazil,	Taiwan,	South	Africa	and	Switzerland	have	already	introduced	a	financial	transaction	tax	to	generate	general	tax	revenues.		Long-term	pledges	by	donors	have	been	used	as	security	to	issue	bonds	in	capital	markets.	The	International	Finance	Facility	for	Immunisation,	established	in	2006,	has	successfully	mobilised	donor	pledges	to	launch	immunization	bonds,	and	to	channel	$6	billion	in	2006-18	to	Gavi	to	accelerate	introduction	of	new	vaccines	and	expand	immunization	programmes	in	LMICs.206		Debt	conversion	has	been	used	to	convert	loans	to	grants	with	conditions	of	meeting	a	health	or	social	target.	For	example,	with	Debt2Health,	a	creditor	country	forgoes	a	portion	of	a	debt	on	 the	 condition	 that	 the	 debtor	 country	 invests	 an	 agreed	 counterpart	 amount	 by	contributing	to	the	Global	Fund	according	to	a	schedule	established	as	a	part	of	a	debt	swap	agreement	which	is	then	provided	as	a	grant	to	expand	national	health	programs	.207	
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	The	 Affordable	Medicines	 Facility	 for	Malaria	 (AMFm)208,209	 has	 pooled	 donor	 funds	 and	negotiated	with	drug	manufacturers	price	 reductions	 for	malaria	medicines	 in	 return	 for	predictable	 and	 increased	 volumes	 of	 medicines	 purchased	 by	 countries	 funded	 by	 the	Global	Fund.	AMFm	then	funded	both	public	and	private	sector	institutions	to	make	available	to	 the	 public	 affordable	 and	 effective	 malaria	 medicines	 and	 displace	 less-effective	treatments	from	the	market.210,	211			Similarly,	the	Advanced	Market	Commitments	Pilot	for	Pneumococcal	Disease210	used	donor	funding	or	pledges	 to	establish	 legally-binding	 long-term	purchase	commitments	 for	new	vaccines	 for	 diseases	 affecting	 children	 in	 LMIC	 at	 pre-negotiated	 prices	 and	 predictable	volumes	for	purchasing	vaccines.			A	promising	funding	instrument	is	a	Social	Impact	Bond,	which	is	created	by	a	government	agency	that	wishes	to	achieve	a	desired	social	or	health	outcome.211	The	agency	engages	an	external	 organization	 to	 achieve	 the	 outcome.	 A	 third-party	 investor	 provides	 upfront	working	capital	to	the	external	organization	as	an	at-risk	investment.	If	the	desired	social	outcome	is	achieved,	the	government	releases	payment	to	the	external	organization,	based	on	terms	specified	in	an	upfront	contract,	which	repays	its	investors	their	principal,	plus	a	return	on	the	investment.	If	the	outcome	is	not	met,	the	government	disburses	no	payment.		A	Development	Impact	Bond	is	a	variation	on	the	social	impact	bond,	where	the	payment	comes	from	an	external	funder	(e.g.	a	development	agency	or	a	charitable	foundation),	rather	than	a	government.212		
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	(vi)	More	effective	and	efficient	allocation	of	available	health	resources:	The	World	Health	Organisation	has	estimated	that	worldwide	around	20-40%	of	all	health	spending	in	health	systems	is	not	used	efficiently	or	effectively.213	With	priority	setting,	which	enables	more	efficient	allocation	of	resources,	governments	could	use	the	available	fiscal	space	more	optimally.	The	potential	savings	are	substantial.	This	could	help	release	funds	for	investing	in	scale-up	of	services	for	childhood	cancers.	
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SECTION	6:	SUSTAINABLE	CARE	FOR	CHILDHOOD	CANCERS:	MAKING	IT	HAPPEN			The	Commission	has	presented	compelling	evidence	to	show	the	large	burden	of	cancer	in	children,	poor	access	to	care	in	countries	where	those	services	are	most	needed,	and	wide	inequities	in	outcome.	It	also	identified	real	opportunities	to	address	the	childhood	cancer	burden	globally,	through	cost-effective	interventions	and	strengthened	health	systems	that	could	prevent	needless	deaths	and	realise	very	substantial	health	gains,	at	the	same	time	as	generating	substantial	economic	benefits.			We	explore	in	this	section	critical	success	factors	with	stakeholder	roles	that	could	help	translate	these	solutions	into	actions,	and	to	realise	the	vision	of	scaling	up	effective	and	sustainable	healthcare	for	children	with	cancer.		
	
Critical	success	factors	for	scaling	up	childhood	cancer	interventions	The	challenges	and	opportunities	in	the	global	fight	against	cancer	and	critical	success	factors	have	been	discussed	in	multiple	fora.214			The	first	critical	success	factor	is	strong	global	and	country-level	leadership,	which	is	currently	lacking	for	childhood	cancers.	This	is	currently	lacking	for	childhood	cancers.	There	is	a	need	for	more	visible	commitment	and	funding	from	the	UN	and	international	development	agencies,	as	well	as	global	and	country	level	leaders	to	halt	a	very	large	number	of	needless	deaths	from	childhood	cancer.	The	recent	WHO	Global	Initiative	for	Childhood	Cancer39	is	commendable.	It	could	mark	the	beginning	of	a	global	movement	to	
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raise	awareness	among	international	agencies	and	governments	about	the	importance	of	addressing	the	problem	of	childhood	cancer	and	advocate	for	strengthening	health	systems	to	provide	optimal	and	sustainable	care	for	children	with	cancer.	Given	the	magnitude	of	the	problem,	however,	much	more	needs	to	be	done.	A	recent	study	which	re-examined	the	ranking	of	cancer	burden	suggest	childhood	cancers	rank	sixth	globally	in	terms	of	total	number	of	DALYs	after	cancers	of	the	lung,	liver,	stomach,	colon	and	rectum,	and	breast,	with	greater	burden	than	cancers	of	oesophagus,	pancreas,	and	cervix.215	Despite	this,	the	attention	childhood	cancers	receive	in	the	global	health	agenda	is	vanishingly	small.		The	second	critical	success	factor	relates	to	the	development	of	a	clear	narrative	for	childhood	cancers	–	a	narrative	that	communicates	a	clear	sense	of	urgency	and	ambition,	and	articulates	a	clear	sense	of	mission,	hope	and	actions	to	achieve	success.		Globally,	there	is	a	lack	of	awareness	of	the	true	burden	of	childhood	cancer,	the	burgeoning	inequities,	the	extent	of	the	crisis,	and	the	availability	of	solutions	that	would	produce	great	health	and	economic	returns.	Instead,	the	cancer	narrative	is	clouded	by	myths	that	it	is	‘complex’,	‘expensive’,	‘difficult	to	diagnose’,	‘complicated	to	treat’,	and	the	narrative	on	childhood	cancers	is	drowned	by	the	broader	discourse	on	non-communicable	diseases	that	focuses	almost	entirely	on	adults.	  			The	third	critical	success	factor	is	the	creation	of	a	diverse	and	inclusive	global	social	movement	that	brings	together	a	coalition	of	partnerships	and	networks,	involving	civil	society,	affected	individuals	and	communities,	health	professionals,	researchers,	funders,	international	agencies,	private	sector,	and	innovators.	Instead,	the	global	efforts	for	
Pre-publication	pre-proofed	version	 94 
childhood	cancer	are	highly	fragmented,	with	no	clear	overarching	global	strategy,	and	characterised	by	a	multitude	of	twinning	relationships,	which	usually	remain	at	project	level.	The	fragmentation	is	compounded	by	the	many	short-term	initiatives,	which	morph	into	one-off	‘pilot	projects’,	but	fail	to	seriously	address	the	needs	of	children	with	cancer.	The	fragmented	landscape	needs	to	change.	It	should	be	replaced	by	an	inclusive,	strategic,	and	large-scale	global	response	to	address	the	large	burden	of	childhood	cancer.	In	particular,	the	empowerment	of	civil	society,	communities	and	people	will	be	critical	for	galvanizing	locally-led	effective	response	and	sustained	change.		The	fourth	critical	success	factor	relates	to	alignment.	Scale	–up	of	services	for	children	with	cancer	should	capitalise	on	the	global	momentum	for	achieving	SDGs,	and	in	particular	UHC.	In	particular,	it	is	critical	to	ensure	that	scale-up	of	services	for	childhood	cancer	are	fully	integrated	with	actions	to	strengthen	health	systems.	This	alignment	will	enable	more	optimal	use	of	available	resources,	enable	provision	of	better	services,	and	help	with	sustainability	of	scale-up.		The	fifth	critical	success	factor	is	innovation	–	with	investment	in	research,	development	and	translation	to	develop	technology-enabled	service	delivery	models	for	providing	care	to	children	with	cancer.	Innovation	is	critical	to	rapidly	address	gaps	in	human	resources,	infrastructure,	diagnostics,	treatment,	care	and	data,	and	generate	local	solutions	for	global	ambitions	and	shared	priorities.			
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A	global	coalition	for	childhood	cancers		A	multisectoral	global	coalition	of	partnerships	and	networks	is	critical	for	the	development	of	a	rapid	and	impactful	response	for	effectively	addressing	childhood	cancers	at	global	and	country	level.	This	partnership	should	be	inclusive	and	involve	governments,	civil	society,	affected	individuals,	groups	and	communities,	health	professionals,	professional	associations,	researchers,	funders,	international	agencies,	the	private	sector	and	innovators.	Each	of	these	actors	has	a	role	to	play.	Each	brings	strengths	and	capabilities	that	could	be	harnessed	to	create	synergies	for	expanding	access	to	care	for	children	with	cancer,	in	order	to	reduce	inequities	and	improve	outcomes	(panel	9).		
	
Panel	9:	Multisectoral	collaboration	and	partnership	to	develop	an	effective	response	
for	childhood	cancers		
Governments	Governments	can	provide	leadership,	by	convening	and	empowering	stakeholders	to	catalyse	a	coordinated	multisectoral	response	for	effective	management	of	childhood	cancers..	Governments	make	political	and	fiscal	decisions	to	allocate	resources	to	priority	areas	and	invest	in	health	in	order	to	meet	current	and	emerging	health	needs	and	ensure	wellbeing	of	their	citizens.	Governments	have	the	opportunity	to	use	the	evidence	generated	by	the	Commission	to	invest	in	the	expansion	of	services	for	childhood	cancers	as	part	of	UHC,	to	improve	health	and	wellbeing	of	children,	and	help	generate	substantial	economic	returns	for	communities	and	countries.		
International	Organizations	
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As	with	governments,	international	organizations	can	play	a	convening	role	to	develop	multisectoral	responses	at	global	and	country	level	with	meaningful	targets,	establish	guidance	on	incorporating	appropriate	services	and	cost-effective	interventions	as	part	of	UHC	expansion	in	countries,	and	help	mobilise	sustainable	funding.	Childhood	cancers	have	not	featured	prominently	in	the	global	discussions	on	financing	and	prioritisation	of	health	challenges.	For	example,	the	Global	NCD	Action	Plan	for	the	Prevention	and	Control	of	NCDs	2013-2020	does	not	mention	childhood	cancers	as	a	priority	area,	nor	does	it	have	any	targets	specific	to	childhood	cancer.	216	Similarly,	the	SDG	3	target	3.4,	“by	2030	reduce	by	one-third	pre-mature	mortality	from	non-communicable	diseases	(NCDs)	through	prevention	and	treatment,	and	promote	mental	health	and	wellbeing”,	has	no	indicators	specific	to	childhood	cancer.217	Nor	do	the	WHO	‘Best	Buys”	for	NCDs,	which	comprise	88	cost-effective	interventions	and	policy	actions,	have	any	interventions	specifically	aimed	at	childhood	cancers.218		Childhood	cancer	has	been	increasingly	embedded	into	WHO	priority	activities	on	cancer	following	the	mandate	of	the	2017	World	Health	Assembly	resolution.38	In	September	2018	WHO	announced	the	launch	of	WHO	Global	Initiative	for	Childhood	Cancer,	which	aims	to	double	the	global	cure	rate	for	children	with	cancer,	improving	average	5-year	survival	of	the	six	commonest	childhood	cancers	(namely,	acute	lymphoblastic	leukaemia,	Hodgkin	lymphoma,	Wilms	tumour,	Retinoblastoma,	Low	Grade	Glioma	and	Burkitt	lymphoma)	to	60%	by	2030,	and	to	save	one	million	lives.39	However,	targets	need	to	be	revised	in	the	light	of	the	new	modelling	and	estimates	developed	by	the	Commission	which	indicates	
Pre-publication	pre-proofed	version	 97 
substantial	underreporting	of	childhood	cancers	in	LMICs,	where	one	in	two	cases	of	new	cases	of	childhood	cancer	are	missed.			The	International	Atomic	Energy	Agency	(IAEA)	(https://www.iaea.org	)	has	played	an	important	role	in	expanding	worldwide	access	to	radiotherapy	and	nuclear	medicine.		Through	its	Programme	of	Action	for	Cancer	Therapy	(PACT)219	IAEA	is	working	with	UN	Member	States	to	reduce	global	inequities	in	cancer	care220,	and	with	WHO	and	the	International	Agency	for	Research	on	Cancer	(IARC	https://www.iarc.fr	)	has	undertaken	imPACT	reviews221	in	around		100	countries.	These	reviews	assess	country	capacity,	identify	priority	interventions	to	address	current	and	future	needs	for	cancer	and	future	work	needed	to	support	countries	in	developing	national	cancer	control	plans,	strengthen	cancer	registries,	identify	funding	and	improve	cancer	services.				Stronger	cancer	registries	are	critical	for	estimating	the	true	burden	of	childhood	cancers.	IARC	is	working	with	countries	to	develop	and	strengthen	cancer	registries,		and	to	establish	standardized	methods	to	better	measure	the	incidence,	and	mortality	for	childhood	cancers.	The	registry	data	collated	by	IARC	for	use	in	its	analyses,	publications	and	in	the	Global	Cancer	Observatory222	should	be	publicly	available	to	stimulate	the	development	of	innovative	methods	of	measurement	and	comparison.	These	data	will	underpin	the	development	and	implementation	of	monitoring	accountability	frameworks	to	measure	regularly	and	compare	country-by-country	progress	in	expanding	access	to	high-quality	diagnosis,	treatment	and	care,	for	children’s	cancers.		
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Civil	Society	Concerted	action	and	advocacy	from	civil	society	has	been	instrumental	in	catalysing	global	movements,	such	as	that	for	AIDS,	which	led	to	the	convening	of	the	UN	General	Assembly	special	session	in	2001	and	the	UN	Declaration	on	AIDS.223	In	addition	to	bringing	a	voice	for	affected	children,	families	and	communities,	mobilising	support	and	building	awareness	at	country	level,	civil	society	can	help	accelerate	capacity	development	and	programme	implementation,	and	hold	governments	to	account.			Civil	society	can	help	shape	the	narrative	on	childhood	cancers	to	frame	childhood	cancer	as	an	integral	part	of	global	commitments	to	UHC	and	health	rights	to	influence	policy	for	expanding	worldwide	access	to	effective	services	for	childhood	cancers.	There	are	good	examples	of	civil	society	initiatives	that	are	providing	a	voice	for	childhood	cancers.	For	example,	Childhood	Cancer	International	(https://www.childhoodcancerinternational.org),	which	is	a	global,	parent-driven,	not-for-profit	entity	for	grassroots	and	national	parent	support	organizations	for	childhood	cancer.	It	represents	188	parent	organizations,	childhood	cancer	survivor	associations,	childhood	cancer	support	groups	and	cancer	societies	in	96	countries.	The	Union	for	International	Cancer	Control		(UICC)	(https://www.uicc.org)	has	played	an	increasingly	important	global	advocacy	and	leadership	role	in	strengthening	the	global	response	to	cancer	by	bringing	together	more	than	1,000	non-governmental	organizations	involved	in	cancer,	mobilising	global	leaders	at	the	World	Cancer	Summit,	and	by	updating	the	World	Cancer	Declaration	with	a	call	to	action	to	reduce	the	global	cancer	burden.224		
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Professional	Associations	Professional	associations	play	an	important	role	in	establishing	professional	standards,	developing	capacity	and	expanding	access	to	high-quality	healthcare	services	for	children	with	cancer.	For	example,	the	International	Society	of	Paediatric	Oncology	(SIOP;	https://siop-online.org),	which	has	affiliated	societies	in	different	regions	of	the	world	such	as	SIOP-Africa,	SIOP-Asia,	SIOP-Oceania	and	the	Latin	American	Pediatric	Oncology	Group	(GALOP),	as	well	as	International	Society	of	Pediatric	Surgical	Oncology	(IPSO	https://ipso-online.org)	is	working	with	international	and	country-level	partners	to	develop	much-needed	human	resource	capacity	through	education	and	training	to	expand	services	in	LMICs.	Professional	associations	have	also	helped	to	establish	or	strengthen	regional	collaborations	to	raise	the	level	of	available	expertise	in	LMICs	through	shared	resources	to	improve	care	and	outcomes	for	children	with	cancer	(appendix	pp.	45-48)	–	platforms	which	could	further	advance	management	of	children	with	cancer	in	low-resource	settings.		
Philanthropic	Organizations	and	Academic	Cancer	Centers	In	LMICs,	philanthropic	organisations	have	played	an	instrumental	role	in	mobilising	donations	and	public	funding	to	establish	centres	to	care	for	children	with	cancer.	These	centres,	which	have	established	twinning	arrangements	with	cancer	centres	in	high-income	countries,	provide	high	quality	services	to	those	who	are	fortunate	enough	to	access	these	services	(Section	2).	There	is	an	opportunity	in	LMICs	to	operationally	better	integrate	the	centres	involved	in	twinning	activities	with	existing	cancer	networks	and	health	systems.	Such	integration	will	help	to	create	synergies	to	more	optimally	expand	access	to	care	for	children	with	cancer.		
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The	private	sector	The	private	for-profit	sector	has	played	an	important	role	in	expanding	services	for	children	with	cancer,	but	generally	for	the	few	who	can	afford	to	pay	for	the	services.	However,	in	many	LMICs,	the	private	for-profit	healthcare	provider	sector	is	not	well	regulated,	and	there	are	no	data	on	the	quality	of	services	provided	or	the	outcomes	achieved.	The	private	sector	is	a	major	funder	of	research	and	development	for	diagnostics,	medicines	and	health	technologies	for	management	of	cancer	in	children,	but	mostly	for	high-income	and	middle-income	countries,	where	profitable	markets	exist.	Public-private	collaborations	could	help	develop	affordable	solutions	for	countries	that	need	them.		Wide-ranging	activities	by	many	committed	stakeholders	have	generated	an	extensive	collection	of	initiatives	for	childhood	cancers	to	grow	capacity,	increase	know-how	and	establish	research	and	service-delivery	platforms	to	benefit	those	able	to	access	them.	However,	many	of	these	initiatives	have	remained	as	projects	and	have	not	always	produced	noticeable	differences	in	access	to	cancer	services	for	all	children	or	have	had	an	equitable	impact	on	cancer	outcomes	at	population-level.	Despite	these	shortcomings,	these	initiatives,	which	have	helped,	provide	valuable	lessons	for	scale-up	of	services	for	childhood	cancers.	They	can	be	used	as	a	foundation	for	scale-up	of	effective	care	for	children	for	cancer.	225	Hence,	it	is	an	imperative	to	better	coordinate	and	combine	global	activities	of	international	agencies,	professional	associations,	civil	society,	foundations	and	the	private	sector	in	order	to	expand	worldwide	access	to	care,	reduce	inequities	and	improve	outcomes	for	children	with	cancer.		
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SECTION	7:	A	CALL	TO	ACTION		
	We	present,	for	the	first	time,	new	estimates	that	quantify	country-specific	and	worldwide	incidence,	mortality	and	survival	for	childhood	cancers.	We	also	provide	new	estimates	for	the	coverage	of	healthcare	services	for	childhood	cancers.	The	results	point	to	worldwide	inequities	and	a	stark	picture	for	children	with	cancer	in	LMICs.	Yet,	childhood	cancer	is	not	complex,	expensive,	difficult	to	diagnose,	or	complicated	to	treat.			There	will	be	an	estimated	413,000	incident	cases	of	childhood	cancer	worldwide	in	2020,	but	181,000	of	these	cases,	almost	one	half,	will	go	undiagnosed.	We	estimate	that	globally	there	will	be	13.7	million	cases	of	childhood	cancer	between	2020	and	2050,	of	whom	around	3.4	million	will	be	in	low-income	countries,	and	an	estimated	6.9	million	in	lower-middle-income	countries.	Our	projections	show	that	at	current	levels	of	health	system	performance	(access	and	referral),	6.1	million	cases,	accounting	for	44.9	%	of	total	cases	of	childhood	cancers	during	2020	to	2050,	will	not	even	be	undiagnosed.	In	low-income	and	lower-middle	income	countries,	the	number	of	children	with	cancer	who	are	never	diagnosed	will	exceed	the	number	of	those	who	are	diagnosed.			In	2020,	there	would	be	328,000	deaths	from	childhood	cancers	globally,	projected	to	rise	to	390,000	by	2050.	The	largest	number	of	deaths	is	projected	to	be	in	lower-middle-income	countries,	reaching	208,000	in	2050,	but	the	largest	proportionate	increase	is	projected	to	be	in	low-income	countries,	rising	from	82,000	to	128,000.	Unaddressed,	we	
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estimate	that	between	2020	and	2050,	cumulatively,	11,108,000	children	will	die	from	childhood	cancer	if	no	additional	investments	are	made	to	improve	access	to	healthcare	services	or	childhood	cancer	treatment.	Of	these	a	staggering	9,344,000	children,	accounting	for	84.1%	of	children	who	die	from	cancer,	will	be	in	low-income	and	lower-middle-income	countries.		As	with	incidence	and	mortality,	there	are	substantial	variations	in	5-year	net	survival	between	countries	by	World	Bank	income	group.		While	in	2015-2019	average	global	5-year	net	survival	was	37.4%,	it	ranged	from	11.6%	in	Africa	to	83.0%	in	North	America.	There	was	a	huge	difference	in	the	modelled	estimates	of	5-year	net	survival	for	all	cancers	combined,	from	7.4%	estimated	for	low-income	countries	to	79.8%	in	high-income	countries.		There	is	very	substantial	underreporting	of	childhood	cancers	in	LMICs,	where	one	in	two	cases	of	new	cases	of	childhood	cancer	are	missed.		Our	findings	indicate	that	the	targets	set	by	the	Global	Initiative	for	Childhood	Cancer	to	double	the	global	cure	rate	for	children	with	cancer,	to	improve	globally	the	5-year	survival	from	childhood	cancers	to	60%	by	2030	and	to	save	one	million	lives	39,	need	to	be	revised		However,	our	results	also	show	that	this	burden	can	be	largely	addressed	with	new	and	additional	funding	for	the	application	and	scale-up	of	interventions,	which	are	known	to	be	cost-effective.		
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There	are	substantial	health	and	economic	benefits	of	investing	in	interventions	to	effectively	manage	childhood	cancers.	Simultaneous	comprehensive	scale	up	of	interventions	could	avert	6,235,086	deaths	in	children	with	cancer	in	2020	to	2050,	representing	more	than	half	(56.1%)	of	the	total	number	of	deaths	otherwise	projected	to	occur.	With	excess	mortality	risk	taken	into	account,	this	reduction	in	the	number	of	deaths	is	projected	to	produce	undiscounted	318.4	million	life-years	gained.		A	with	health	benefits,	the	economic	benefits	of	Comprehensive	Scale-up	are	substantial.	Cumulative	productivity	gains	would	exceed	the	cumulative	costs	in	lower-middle	income	countries,	middle-income	countries	and	high-income	countries	in	the	period	2020	to	2050,	and	beyond	2050	for	low-income	countries.	The	global	lifetime	productivity	gains	of	$2,580	billion	in	2020	to	2050	would	be	four-times	greater	than	the	cumulative	treatment	costs	of	$594.4	billion,	producing	a	net	benefit	of	$1,986.1	billion	on	the	global	investment.	This	would	represent	a	net	return	of	$3	for	every	$1	invested.			For	all	country	income	groups,	the	overall	lifetime	productivity	gains	would	exceed	cumulative	treatment	costs	to	generate	very	substantial	net	benefits	and	a	positive	return	on	investment.		We	provide	compelling	new	evidence	that	investment	for	comprehensive	scale-up	of	interventions	not	only	enables	treatment	of	children	with	cancer	worldwide	to	avert	more	than	6	million	deaths,	save	in	excess	of	300	million	life	years,	but	also	brings	almost	$2	trillion	in	positive	economic	benefits.		
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	Our	findings	also	suggest	that	successful	implementation	of	effective	childhood	cancer	services	is	feasible,	even	in	low-income	countries	to	achieve	the	goal	of	improving	outcomes	for	children	with	cancer.		We	propose	six	major	actions,	with	targets	to	achieve	this	important	goal.		
Action	1:	incorporate	childhood	cancers	in	essential	benefits	packages	when	
expanding	universal	health	coverage		Care	for	childhood	cancers	must	be	incorporated	into	national	essential	benefits	packages	when	expanding	UHC,	with	explicit	targets	for	comprehensive	scale-up	of	capacity	in	health	systems	to	expand	the	coverage	of	effective	services	for	childhood	cancers.		
Target:	by	2030,	as	part	of	the	efforts	to	expand	UHC,	at	least	80%	of	LMICs	should	incorporate	appropriate	level	of	effective	services	for	childhood	cancers	in	their	essential	benefits	packages	and	ensure	their	financing	and	provision	to	expand	access	to	all	children	with	cancer	in	their	country.			
Action	2:	develop	national	cancer	control	plans	and	provide	predictable	financing	to	
ensure	expansion	of	sustainable	care	for	children	with	cancer	Predictable	financing	is	critical	for	comprehensive	scale-up,	both	for	sustaining	services	and	for	preventing	interruptions	to	care.	Countries	of	low-income	and	middle-income	should	develop	fully	costed	national	cancer	plans	that	articulate	how	sustainable	cancer	care	for	children	could	be	progressively	developed	and	funded.	
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Target:	By	2030	at	least	80%	of	LMICs	should	have	national	cancer	control	plans	that	articulate	specific	actions	and	targets	for	achieving	sustainable	care	for	children	with	cancer,	with	defined	processes	for	creating	the	necessary	fiscal	space	for	funding	this.		
Action	3:	eliminate	out-of-pocket	expenditures	for	children	with	cancer	to	halt	
catastrophic	expenditures	and	abandonment	of	treatment		Countries	should	eliminate	co-payments	and	out-of-pocket	expenditures	for	direct	and	indirect	costs	incurred	by	children	with	cancer	when	they	are	receiving	care	to	prevent	catastrophic	expenditures	and	to	eliminate	treatment	abandonment.	Countries	should	also	work	with	partners,	such	as	local	NGOs	and	foundations,	to	address	needs	of	children	and	their	families	beyond	direct	cancer	services	(including	transportation,	housing	and	meals),	especially	for	vulnerable	families	where	these	unmet	needs	contribute	to	treatment	abandonment	risk.	
Target:	At	least	80%	of	LMICs	should	eliminate	out-of-pocket	expenditures	for	children’s	cancer	services	by	2030.	
	
Action	4:	expand	access	to	effective	services	for	childhood	cancers	by	establishing	
cancer	networks	We	urge	immediate	action	in	all	LMICs	to	create	national	and	regional	cancer	networks	or	expand	them	where	they	exist,	in	order	to	establish	appropriate	capacity	for	providing	packages	of	effective	services	based	on	evidence-based	guidelines	to	at	least	80%	of	children	with	cancer.	
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Target:	by	2030,	increase	the	capacity	of	human	resources,	diagnostics,	treatment,	surgery,	radiotherapy	and	social	support	in	LMICs	to	expand	coverage	of	effective	services	and	palliative	care	to	80%	of	children	with	cancer,	and	pain	control	to	100%	of	children	with	cancer.		
Action	5:	invest	in	the	development	of	cancer	registries	that	incorporate	childhood	
cancers	Data	and	evidence	are	important	for	guiding	country	priorities	and	actions	to	address	childhood	cancers.	Yet,	reliable	data	on	childhood	cancers	are	all	but	absent	in	LMICs.	Population-based	cancer	registries	are	essential	for	quantifying	the	determinants,	the	incidence	and	survival	for	cancer	in	children.	To	estimate	survival,	cancer	registries	must	also	be	able	to	link	their	tumour	registrations	to	national	or	regional	databases	of	deaths	from	any	cause	on	a	routine	basis.	Efficient	vital	statistics	systems	on	births,	deaths	and	populations	are	also	required.			
Target:	by	2030,	at	least	80%	of	LMICs	should	establish	data	systems	and	population	based	cancer	registries,	with	the	requisite	legislative	and	financial	support,	to	collect	data	on	childhood	cancers,	including	incidence,	stage	and	survival,	and	to	link	their	data	routinely	with	data	on	all	deaths.	
	
Action	6:	invest	in	research,	development	and	innovation	Currently,	research	funding	related	to	childhood	cancers	is	small,	highly	fragmented	and	largely	inaccessible	to	researchers	outside	high-income	countries.	Lack	of	available	solutions,	suboptimal	care	and	the	absence	of	affordable	interventions	hinder	
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achievement	of	health	outcomes	for	children	with	cancer.	Investments	in	research	infrastructure,	research	based	in	LMICs,	and	innovation	is	needed	to	expand	the	use	of	available	interventions.	This	will	help	create	affordable	and	accessible	solutions,	to	translate	research	outputs	into	scalable	and	impactful	solutions	for	children	with	cancer,	but	importantly	to	develop	novel	innovative	service	delivery	models	that	are	appropriate	for	LMICs	and	do	not	necessarily	replicate	models	of	care	from	high-income	countries.		
Target:	The	United	Nations	should	spearhead	the	establishment	of	a	global	coalition	to	achieve	the	goal	of	sustainable	care	and	an	‘Innovation	Fund	for	Childhood	Cancer’.	This	fund	should	have	the	mission	to	pool	and	improve	coordination	of	disparate	funding	streams,	and	to	fund	research	and	innovation	in	LMICs,	with	a	target	of	mobilising	$100	million	per	year.			In	particular	the	funding	should	be	used	for	the	development	of	affordable	solutions	for	children	with	cancer	in	LMICs,	implementation	studies,	and	multi-centre	prospective	studies	to	elucidate	effect	of	treatment	in	different	contexts	with	varying	socio-economic	and	genetic	backgrounds.			No	one	can	doubt	the	huge	challenges	that	many	countries	face	in	relation	to	childhood	cancer.	However,	the	improved	outcomes	for	childhood	cancer	achieved	in	many	countries	over	the	last	five	decades	bring	hope.	The	availability	of	cost-effective	interventions,	evidence	for	the	feasibility	of	scaling	up	their	application	at	a	global	level,	and	the	compelling	economic	case	for	investment,	for	investment	in	improving	the	survival	from	childhood	cancer,	provide	inspiration	for	further	progress	over	the	next	generation.			
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Success	will	be	realised	through	political	leadership,	global	solidarity,	collective	action,	inclusive	participation	of	all	major	stakeholders,	and	alignment	of	country-level	and	global	efforts	to	expand	access	to	effective	and	sustainable	care	for	children	with	cancer.			Only	then	can	all	children	who	are	diagnosed	with	cancer	be	able	to	enjoy	equitable	access	to	optimal	care,	better	health,	the	chance	to	reach	a	fulfilling	and	productive	adulthood,	and	the	dignity	that	they	deserve.					
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